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ABSTRACT 
A progra m of e x perime nt s comparing t he formulatio n of 
rac - ibuprofen to t h at of ( - )-S- i buprofe n was pe r f or med. 
Early i nve s tigat i on s revealed that al t h ough complying with 
t he Uni t ed Stat es Pharmac opeia c ompendial standards five 
different sources of rac-ibuprofen had different processing 
characteristics and as a result variable biopharmaceuti c al 
properties. Crystal habits critically influenced process ing 
parameters. It was possible t o identify l ow and h i gh liquid 
requirement powders for the wet granulation end - point. 
Further analysis of rac - ibuprofen crystals was performed 
during the different stages o f tablet manufacture . Phase 
diagrams c onfirmed that rac - ibuprofen crystallizes preferen-
tially in the monoclinic space P2 1 c group as a true 
racemate . It was found that crystal distortion translated 
int o an hydrophobic network of ibuprofen causing a dr op of 
8.5 KJ mole - 1 in the enthalpy of fusion. This is thought t o 
be responsible for the poor performance of ibuprofen 
tablets. The extent of this network seemed to be dose de -
pendent as suggested by the dissolution profiles. 
Using single crystal x-ray diffraction. the crystal lat -
tice of (+)- S- Ibuprofen was elucidated a nd the molecular 
pharmaceutics of the S and racemate investigated . The (+) 
isomer. although crystallizing with the same number of 
molecules in the unit cell. exhibited a t otally independent 
crys~al ~ith a mel~ing point of 54°C a~d a~ enthalpy of fu -
sion ( c.E ) of 17 . 9 -1 KJ mo le less. ".'he stereoisomer of 
ibuprofec was more soluble than rac - ibuprofen in aqueous 
media . However , a study of the solution thermodynamics 
revea::.ed that standard free energy of s olution ( L>G o = 
rac 
30.3 
and t>G o = 29.5 in KJ mole ) were comparable. whereas heats s 
and entropy of solution were very different at pH 1. 3 
( L>H = 
rac 
32. 2 and L>HS = 51 . 5 in KJ ! mole ) . The small 
specific surf ace area of the s isomer ( 2.8.10-3 m 2 g ) com-
pared to the racemate (0. 34 m2 1g ) is pr obably responsible 
for the slower intrinsic dissolution ( IDRrac = 11.6 
µg . sec - 1 .cm-2 ) . The study of 
biopharmaceutical properties of (+)-S- Ibuprofen f ormula-
tions. however , indicated an excellent flow and better 
dissolution than the racemate . Extensive eutectic behavior 
of the S(+) stereoisomer might be of some concern to the 
formulators. 
In order to formulate the pure enantiomer. the phar -
macokinetic of rac - ibuprofen was investigated. Using the 
Stellatm simulation software it was determined that 1 / 3 of 
the (+)- S- Ibuprofen was derived from the inversion of (-)-R-
ibuprofen systemically rather than pre - systemically. Thus 
150 mg of (+)-S-ibuprofen might be therapeutically 
alent to 200 mg of rac-ibuprofen . 
equiv-
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PREFACE 
I elected t o write this dissertation following the for-
mat of the manuscript plan described in section 11-3 of the 
Graduate manual at the University of Rhode Island. This op-
tion was most appropriate to present my results in several 
sections. 
Section I consists of a general presentation of the 
problem with introduction and objectives of my investiga-
tions. The five manuscripts. chronologically numbered in 
Section II. are the core of this study . Most of the papers 
have been either accepted or submitted for publication. 
Section III. a published manuscript on the topic of clinical 
research. was not directly related to the core of this work. 
but some of the analytical method was later employed in the 
pharmacokinetic methodology used for the (•)- S- ibuprofen. 
Section IV is a set of appendices A to D giving ex -
perimental details on this work. 
vi 
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SECTION I 
INTRODUCTION 
The production o f pharmaceutical compressed tablets is 
very common despite the fact that our understanding of the 
process is by n o means complete. In many instances. the 
choice of formulati on variables is based on an intuit ive 
rather than a rati onal function . Thus the processing tech -
nology may or may not be optimal . As a result there are 
problems in fully validating the process as required by the 
Food and Drug Administrati on ( FDA ). 
Ibuprofen is currently administered as a racemate and~ 
oral dosage forms are manufactured using wet granulation. 
This technology improves the flow and compactibility of pow -
ders by increasing the particle size and cohesion . The 
effect of processing on crystal and granule characteristics 
have been carefully discussed in the literature . The dis-
tribution of particle size depends substantially on the 
binder solution (1). its volume ( 2 ) . the mixing time ( 3 ) and 
many other factors ( 4 ). The drying stage may have critical 
effects on the hardness ( 5 ) and other physical properties of 
the granules ( 6 - 9 ). Several authors have correlated compac -
tion parameters to the granule characteristics ( 10- 12 ) 
Similarly . the properties of pharmaceutical tablets such as 
dissolution ( 13- 16 ), disintegration time ( 16 ) or hardness 
( 14 ) , were related to the primary processing technology. To 
date it is generally recognized that some characteristics of 
2 
the r a~ materials are responsible f or c ertain a spe cts o f t he 
pr oce ss ing behavior ( 16- 21 ) . Althou gh g ranu l e gr owth 
mech anisms have been studied rather successful l y ( 17.21 - 25 ), 
the the oreti c al models proposed fail t o explain some am -
biguities of the ibuprofen formulati on. There are a number 
of articles describing the relationship betveen the 
molecular behavior of povdered drugs and tablet processing 
( 26-29 ) . These studies addressed the crystal modifications 
of carbamazepine(28), sulfanilamide ( 29 ) . phenobarbital(30 ) . 
aspirin ( 31 ) or many other drugs ( 32 ) but at this time. there 
are no such publications for ibuprofen. 
The development of ibuprofen , a non steroidal an -
tiinflammatory agent ( NSAI ), with several doses strengths 
presents many challenges (33) to the formulators. Yet. new 
challenges emerge from the recent possibility of manufactur -
ing the biologically active stereoisomer [( +)- S- ibuprofenl 
using an economically viable chemical synthesis . 
During the course of this study ( Spring 1990 ) . we vere 
able to obtain a substantial amount of (+)-S-ibuprofen. At 
the time several prestigious pharmaceutical companies 
( Johnson & Johnson. Merck Sharp & Dohme and McNeil ) were ac-
tively investigating possible synthetic routes to obtain the 
(+) isomer in a large scale fashion and presently the 
benefits as well as possibilities of formulating this com-
pound are under heavy scrutiny . This general interest in 
stereospecif ic drug development meets the new trends in 
3 
regul a to r y bodies . especially t he FDA under the leader s hip 
of Carl Peck. in promocing the pharmaceutical devel opment of 
pure pharmaco l ogically active enanciomers. 
With the exception of Napr oxen ( Sy ntex ). all profens 
currently used as antiinflammat or y products in the United 
States are marketed as racemates ( 34 ). In most of chese 
cases, the 
responsible 
dextrorotary or S 
for che therapeutic 
optical isomer seems to be 
activity that is the 
stereospecific inhibition of the cyclooxygenase and further 
the prostaglandin synthetase. Various pharmacokinetic 
reports have been published. suggesting that for some of~ 
these aryl propionic acids bioinversion of the inactive 
stereoisomer could 
mechanisms ( 35 ) . 
take place in vivo by enzymatic 
While it was my intention to investigate the relations 
between processing and ibuprofen crystals at a molecular 
level, (in order to improve and optimize ics formulation ), 
it would have been unreasonable to consider sol ely the 
racemate at this stage. Therefore during the spring 1990 I 
decided to redirect my research work with an emphasis on 
comparing the rac-ibuprofen to ( +) -S - ibuprofen crystals. As 
a result, a combination of several "expertise " some ex -
clusively reserved to basic research (i.e. single crystal X-
Ray diffraction ) were applied to the study of the active 
isomer. The hypothesis were that ibuprofen crystal was 
modified during formulation and in turn influenced the 
4 
pr ope r ties o f resulting f ormulac i ons . We a l s o hypothe s ized 
chat . using similar techniques the f ormulati on o f the 
b i ologically active scereoisomer was indeed possible. 
My review of the published literature indicated that 
predicting or understanding the molecular behavior of 
ibuprofen under processing had never been reported. On the 
chirality issue. most reviews on the topic approached the 
problem from a pharmacodynamic or drug metabolism point of 
view ( 33 , 36). There were no published reports investigating 
the possibility of developing the pure ibuprofen enantiomers 
nor addressing the issue of stereospecif ic drug development-
in terms of molecular pharmaceutics. It is believed that 
this approach is a unique concept in the development of pure 
enantiomers that can be used in many othe r comparable cases. 
The specific obj ectives of this research work were 
1 ) to demonstrate the effect of ibuprofen crystal on the 
processing and biopharmaceutical properties of resulting 
formulations 
2 ) to assess crystal distortion qualitatively and 
quantitatively during formulation 
3 ) to use these crystal properties in the development of 
the pharmacologically active (+)-S-ibuprofen 
4 ) and to compare the molecular pharmaceutics of 
racemate and the S enantiomer 
5 
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MANUSCRIPT I 
INFLUENCE OF DIFFERENT SOURCES 
ON THE PROCESSING AND BIOPHARMACEUTICAL PROPERTIES 
OF HIGH DOSE IBUPROFEN FORMULATIONS 
10 
ABSTRACT 
It is known that depending on the manufacturing and 
synthetic processes. drugs may exist as different forms. As 
a result. physico-chemical properties. compression charac-
teristics. intrinsic dissolution and bioavailability may 
vary substantially . The purpose of this study was to inves -
tigate the effect of different sources of ibuprofen on the 
processing of tablets and on their properties . Another em-
phasis o f this work was to rational ize one or s everal key 
characteristics of the raw material as directly related to-
wet granulation parameters and to the behavior of final 
tablets. Commercially available ibuprofen was obtained from 
different 
eluding 
manufacturers and a preformulation program , in -
X- ray crystallography. differential scanning 
calorimetry. scanning electron microscopy , determinati on of 
particle size distribution and fl owability , was performed to 
characterize the raw material. Granules were prepared with a 
planetary mixer and liquid requirements for the end - point 
were obtained by monitoring power consumption. Tablets were 
manufactured on Stokes rotary and single punch instrumented 
presses . Data acquisition interfaces produced compression 
data for each formulation. Granules and final tablets were 
analyzed for hardness , 
uniformity. Statistical 
dissolution profiles and content 
evaluations using analysis of 
variance and multiple comparison procedures were performed 
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on the re s u lts to decermine the s i gnificance o f the 
variabili t y be tween independent paramecers. The ibuprofen 
tested was f ound c o be a unique p ol y morphic form wi t h some 
diffe r enc e s in the external c r ystal linity . The particl e s ize 
characteristics of the material also allowed a differentia-
tion between s ources and although there was no differences 
in dissolution patterns or content uniformity. particle size 
was f ound to account for 50% of the variability in tablet 
hardness . Two sources of ibuprofen with l ower mean particle 
size showed significant variations in end - point liquid re -
quirements resulting in variable tablet crushing strength . 
I NTRODUCTI ON 
It is now widely recognized that grade variability 
of the starting material can be responsible for major dif -
ferences when processing and formulating ( 1 ) oral solid 
dosage forms. Inadequate control of the synthetic process 
can lead to the production of different polymorphs or crys-
tal forms having variable intrinsic dissolution and 
exhibiting differences in 
behavior ( 3 ) or wet 
bioavailability ( 2 ) , compaction 
granulation parameters ( 4 ) . Those 
phenomena have been frequently addressed in the pharmaceuti -
cal literature. For example. the changes in molecular 
pharmaceutics resulting from grinding , compression and in 
general processing, have been discussed extensively ( 5 ) . The 
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kn owl edge o f phy s ico - chemical characteristics of the s cart -
i ng material s i s critical f or the f ormulat or (6 ) . es pe c ially 
when high dose drugs are formulated. where the nature of the 
active itself can also influence subs tantially the process -
ing of the final products. To date . although. industrial 
pharmaceutical specifications recommend two suppliers for 
materials used in a formulation . it has been shown thac 
small changes may occur between products from different 
manufacturers and within products provided by a same sup -
plier ( 7 ) . As a result, formulation problems arise when 
processing the corresponding formulations (4 ) . It is the-
role of the formulating pharmacist t o understand and monitor 
the transfer of technology involved in switching sources or 
suppliers. in order to avoid nonideal or unexpected behavior 
during large scale manufacturing. therefore insuring the 
good quality of a drug product to guarantee the patient ' s 
safety. Ibuprofen, our model compound. is a widely used OTC 
Non Steroidal Antiinflammatory Agent. Different polymorphs 
of recrystallized ibuprofen have been shown to exhibit vari -
able extent and rate of biological absorption (2 ) and this 
molecule could exist under different crystal forms depending 
on the synthetic process. As many therapeutic applications 
of ibuprofen may become available for children at low dose 
levels (B ). minor changes in the crystal structure could 
result in dramatic changes in the pharmacologic disposition 
of this compound. The objectives of this investigation were 
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to determine if several sources of ibupr ofen could exist as 
dif:erent forms and exhibit variations in their physical 
pharmacy p r ofile . A correlation between s ome characteristics 
of the raw material. processing parameters and properties of 
the final products was studied. In further studies . the ef-
fect of processing on ibuprofen is investigated in more 
detail and at a molecular level. For example. it has been 
shown that particle size (9). particle morphology ( 4 ) and 
surface area ( 10 ) of the starting material can influence 
significantly granule formation and binding properties 
during compaction . 
Fractional factorial designs were utilized to in-
vestigate the extent of variability between the different 
sources and multiple comparison procedures were performed on 
the results for processing parameters and biopharmaceutical 
characteristics. This study is the first of a three paper 
serial investigation leading to the optimization of some 
aspects of ibuprofen formulation. The information obtained 
in this work served to correlate key material characteris-
tics to product properties , isolate them from processing 
parameters and support recommendations regarding the use of 
different validation procedures for various raw materials if 
they are provided by different suppliers as it is the case 
in most industrial pharmaceutical settings. 
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EXPERIMENTAL 
MATERIALS 
Ibuprofen was obtained through intermediate dis -
tributors and manufacturers. The identity and origin of the 
five different sources analyzed in this study are presented 
in table I. Monobasic phosphate and sodium hydroxide were of 
analytical grade and obtained through the Fisher Scientific 
Company. Ibuprofen standards for calibration purposes were 
obtained from the Drug Standard Division o f the United_ 
States Pharmacopeial Convention in Rockville , MD. Wet 
granulations containing Fast flow Lactose (Schieffield). 
Povidone ( GAF Co. ). Explotab ( Edward Mendell ) were prepared 
using purified water. Lubrication was performed with 
Magnesium Stearate ( Fisher Scientific Co. ). 
METHODS 
GRANULATION PROCESS 
Ibuprofen was formulated at three different 
strengths , in order to study the effect of increasing 
amounts of active on the processing and biopharmaceutical 
properties of the final products. The formulation inves-
tigated in this work may not be the most appropriate for 
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large scale manipulations. Nevertheless. it was the most 
convenien~ combinat ion available. given the complexity of 
variables i nvolved in the wet granulation process. thus 
unabling the study of pure s ource effect. 
Blends composed of the active. the diluent. the 
disintegrant and the binder were dry mixed for ten minutes 
in a Turbular mixer. The mixture was transferred on an in-
strumented planetary mixer ( Kitchen Aid Model K5 - A Hobart ) 
interfaced with an IBM personal computer. A data acquisiti on 
software from Extech Co . allowed the recording of Power con-
sumption . The pre-mixed powder was then dry mixed in the-
planetary mixer allowing the Watt - reading to stabilize t o a 
baseline (11) . The granulating fluid was added to the mix-
ture using a peristaltic pump at a rate adjusted t o 10 
ml / min. with five seconds interruption every minute. Wet 
granulation was proceeded until the end point. In order to 
have a uniform distribution of liquid bridges the mixer was 
stopped three minutes after the end-point.The power data was 
plotted against the granulation time which corresponds to 
the real wet mixing time and the volume of water added was 
recorded Although we fully understand the importance of 
time and rate at which the liquid is added, it was not the 
scope of this investigation to study this aspect of the 
granulating process Granules were then gently hand 
screened through a number 8 mesh screen and dried at 40°c 
during 12 hours in a convection oven to reach a one to two 
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percent final moisture content. The dry granules were 
screened through a • 16 mesh screen. mixed for ten minutes 
with the lubricant and the appropriate amount of disin-
tegrant. and compressed into tablets on an instrumented B-2 
Stokes rotary press. An instrumented single punch press ( F3 -
Stokes) was used to validate 350 mg tablets with acceptable 
tensile strength ranging from 8 to 15 Sc. The compaction 
force was recorded and the different formulations compared 
using this parameter. Another experiment was conducted and 
the hardness of tablets , made at the same level of compac-
tion. was recorded . Three different levels of compression-
force were investigated as some biopharmaceutical properties 
are known to be proportional to the compaction behavior 
( 12 ). Compression data were recorded as fingerprints of each 
formulation. Table II shows the starting formulation. 
PRKFORMUI.ATION AND PHYSICAL TESTING 
Analytical testing was performed at different 
stages of the study and during the formulation process ( 8). 
The five d ifferent sources of raw material were screened 
through a sol id state preformulation program to characterize 
the active . Thi s preliminary testing included the following 
analysis: 
-particle size analysis 
-surface area determination 
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-differential scanning calorimetry 
- x - rays diffraction patterns 
- scanning electron microscope 
phot ographs 
This reduced physical pharmacy profile was under -
taken to detect any remarkable differences between sources. 
The particle size was characterized on ibuprofen water 
suspensions ( 10 mg 1 ml ) with a Brinckman Particle Size 
Analyzer model 2334A using a laser light scattering tech -
nique . Surface area was determined using a gas adsorption .~ 
monolayer method and calculated using the B.E.T. equation. 
This technique was available on a Quantasorb Sorption 
Analyzer from Quantachrome , NJ. The melting processes were 
measured by differential scanning calorimetry on a Perkin-
Elmer Thermal Analysis Series 7 interfaced with a Perkin-
Elmer P7500 E computer. X-Ray crystallography and scanning 
electron microscopy photographs of the raw materials were 
performed by the Analytical R&D services of Ciba-Geigy in 
Ardsley. NY . Flowability measurements were obtained with a 
custom designed recording powder flow meter on ibuprofen 
powders and granules; a powder flow linearity index was 
derived from the flow charts when applicable (13). Apparent 
tapped density was recorded with an Erweka tap density 
tester with 2000 taps. Statistical evaluation with analysis 
of variance was used to differentiate between independent 
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variables and support interpretations . Final granule size 
was measured using a conventional sieve method. the size 
distributions were compared by plotting the percentage over -
size vs the amount of active on the screen .The median point 
wa s used as the mid - point to compare the different formula -
tions. Mois ture contents and loss on drying profiles we re 
determined on a Computrac Moisture Analyzer from Computrac 
Co. NJ. Tabl et c rushing s trength was measured on an Erweka 
Aut omated Hardness tester. Dissolution testing was performed 
with an Easylift model 63 - 734-100 from Hanson Co. The method 
consisted of a rotating paddle at 50 RPM in a pH 7.2 USP~ 
phosphate buffer at 37°c . In order to avoid time consuming 
dilutions. the working wavelength was adjusted to 264 
nanometers. This technique was applied successful ly in a 
previous work (1 4 ). Gr anulations were tested for moisture 
content, l oss on drying curves. liquid requirement s for 
granulation end point, f l owability and size distribution. 
Ibuprofen cores were analyzed f or hardness and dissolution 
profiles in correlation t o compaction forces. 
RESULTS AND DISCUSSION 
PREFORKULATION 
The preformulation profiles of ibuprofen showed 
several differences in the solid state characteristics of 
19 
the various sources. Neveroheless . it is underst ood that 
analy tical testing can present s ome variations and one has 
t o be extremly cautious with interpretation. For example. 
the ibuprofen- water suspensions used with the particle size 
analyzer may be a fraction not representative of the overall 
sample populations and each analysis was performed in 
triplicate. The mean particle sizes and log-normal frequency 
size distributions are given in table III and figure 
respectively. Both measuremen•s were performed on ibuprofen 
particles suspended in an inert solvent and micronized for 
ten minutes to obtain uniform suspensions. we believe that-
the micronization divided the aggregates into primary par-
ticles but did not generate sufficient energy to dislocate 
the primary crystals related to processing characteristics. 
Further experiments including a study of the effect of in-
creasing micronization time on particle size will be 
performed. The average particle size was obtained from the 
surface weighed equation (15). It is appreciated that sam-
pling may also be subject to certain variation in this case. 
The Francis High density had the largest mean particle size 
with a right skewed tendency. The Cheminor source seemed to 
exhibit a narrow distribution with an intermediate average 
particle size. The Boots and Francis Low density sources ex-
hibited the lowest mean particle size , with the narrowest 
distribution of almost 100% of the sizes below 25 
micrometers. The surface area results of unmicronized 
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ibuprofen samples are presented in table IV . The v olume -
surface measurements of average parcicle size are mostly 
used for pharmaceuticals because they are inversely propor -
tional to the specific surface. Combined with surface area 
measurements. it allows an accurate evaluation of physical 
properties of medicinal powders. Some BET results were not 
expected as Francis low D. and Boots . which exhibited the 
l owest mean particle size, had intermediate surface area 
values. On the other hand , Francis High D. which showed the 
largest mean particle exhibited the highest surface area in -
dicating a very broad size distributi on in accordance with~ 
the frequency curve. The apparent tapped densities reported 
in figure 2 summarize the micromeritics behavior of 
ibuprofen powder based on the previous experiments . 
According to the packing theory , as a result of size charac-
teristics and surface area, Franc is High D. exhibited the 
largest density. Boots and Francis Low D. showed the smal-
lest apparent density. probably indicating the unif ormity of 
the shape distributions. Figures 3-4 are scanning electron 
microscopy photographs of ibuprofen raw material . The mac-
roscopic observation of X500 magnified ibuprofen crystals 
allowed rational conclusions on the differences between 
sources as sorted by particle size , BET values and density 
results . There was no significant visible difference between 
Ethyl and Boots , which exhibited lamellar needle type crys -
tals . On the other hand , Francis low D. has a very uniform 
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distribu•ion of the smallest needle type particles. Francis 
high D. has the largest rounded macrocrystals with small 
microcrystals and Cheminor exists as laminated square plates 
of intermediate size. The surface of Francis High density 
macrocrystals seems to be very irregular. probably an ex-
plaination of the high surface area value. Clearly. this 
visual evaluation indicated that the final crystallisation 
step of the synthetic process could be very different for 
the various sources leading to differences in crystal formE. 
This observation could not be predicted from the BET results 
which did not show any significant differ e nces between~ 
Cheminor.Ethyl and Boots but appeared to vary from the sur-
face area of the two Francis sources as indicated by an F-
test. The thermal analysis gave more information on the 
crystal structure. All the DSC curves exhibited a unique en-
dotherm in the range 75-76°c with enthalpies of fusion 
ranging from 113 J i g to 118 J i g. An example of a typical DSC 
profile of ibuprofen is shown in figure 5 and all melting 
points are reported in table V. An analysis of variance did 
not show any significant differences indicating that the 
ibuprofen tested do not exist as different polymorphic forms 
and the internal crystal structure is equivalent for all 
sources. Nevertheless. the enthalpies of fusion are statis-
tically different. The results of an F-test , shown in table 
VI. suggest that ibuprofen has variable crystal surface 
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structure. as anticipated from the scanning electron micros -
copy photographs and the X-ray diffraction patcerns in 
figure 6. The general shapes are similar for all sources 
however. for low angles of the spectra. the intensity of the 
first deflection peak varies between materials indicating a 
difference in external crystallinity. Except from Francis 
high D. which exhibited a flow index of 18.5 ( a flow index 
of 19 is representative of good flowability properties ) all 
ibuprofen powder did not flow through the orifice of the 
flowmeter. 
The wet granulation process divided the sources into two~ 
groups: raw materials with l ow liquid requirements for the 
end-point ~figure 7) and crystal s with high liquid require-
ments ( figure 8). It is appreciated that the power scale 
does not represent means of differentiating between sources. 
rather the general shape of the power consumption curves was 
analyzed in detail with emphasi s given to the inflection 
points where the torque required to rotate the paddle at the 
same speed within the wet granules increased suddenly. The 
increase in wattage was attributed to a change in the physi -
cal state of the wet mass, which we associated with the end -
point of the granulation also represented by the arrows on 
the power consumption curves. The addition of water was in-
terrupted upon observat ion of this increase. The arithmetic 
average of liquid requirements are reported in table VII. 
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This categorization between sources was not performed ar -
bitrarily but using an analysis of variance and Duncan ' s 
mulciple comparison procedures which divided the raw 
materials into two groups with a 95% confidence level ( table 
VIII ) . Ibuprofen powders with high liquid requirements and 
ibuprofen sources with low liquid requirements. As a conse -
quence of end point requirements. the moisture content of 
the wet mass. measured ac 65°c before the drying step ex -
hibited differences recorded in table IX. Loss on drying 
profiles ( figure 9 ) were also different probably indicating 
variations in the channels and pore tortuosity of the~ 
granules in which the moisture migrates to the surface to 
evaporate. Granules from different sources were mixed with 
lubricant for ten minutes and tabletted. An acceptable com-
paction force was applied (10-15 KN ), the hardness of the 
corresponding tablets measured and reported in table X. 
Several comparison procedures were applied to evaluate the 
effect of independent variables such as particle size or 
amount of active. Although, not using an interactive model. 
some inferences could be made on the size effect with the 
ANOVA in table XI. The sum of square due to the particle 
size of the raw material demonstrated that about 50% of the 
hardness variability among granulations was due to dif -
ferences in particle size fraction and distribution of the 
starting material. The differentiation and classification of 
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the sources by liquid requirements was confirmed on the com-
pacti on versus hardness investigation. The crushing strength 
of tablets made with Boots and Francis Low D. sources was 
higher for the same level of compression forces as compared 
to the other powders. Dissolution profiles of ibuprofen 
cores did not indicate any significant differences in the 
release from the various formulations and based on the pre-
vious preformulation experiments, we 
problems of biological availability with 
do not forecast any 
the use of dif-
ferent sources. Further studies will include the analysis 
for the enantiomeres of ibuprofen . Figure 10 shows the. 
various dissolution profiles and calibration curve for the 
ibuprofen cores. In order to preserve the clarity of the 
figure. the percentage dissolved after 70 minutes are not 
represented as they did not bring further information on 
possible differences between sources. Figure 11 shows a com-
plete dissolution profile of ibuprofen cores made with one 
source (Cheminor ) . The low disintegrant level ( 1% ) and its 
position in the tablet formulation (100% intragranular) are 
responsible for the slow ibuprofen release rate. Further 
studies include the optimisation of the concentration and 
position of the disintegrant when the active / diluent ratio 
is increased. 
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CONCLUSIONS 
The process of chemical synthesis or isola0ion of 
drug substances and excipiencs used in tablet formulation 
although designed to produce materials of reproducible high 
chemical purity , may not necessarily result in batches of 
product with equivalent physico-technical properties . The 
nature of the solvents or the concentration of intermediates 
present in the liquors used for crystallisation can affect 
particle morphology including crystal dislocations. surface 
rugosity and surface area. Those properties. although not. 
reflected in significant differences in melting points. 
solubility or crystal forms. can influence compression 
characteristics and possibly the amount of granulating fluid 
required to produce a coherent mass. This conclusion under-
lines the importance of the preformulation and in-process 
testing when using different suppliers and possibly dif-
ferent batches of the same material. 
As the different ibuprofens tested did not exhibit 
major variations in physical-chemical properties and d o not 
exist as different polymorphs, various sources of this ac-
tive could be used in oral solid dosage forms without risks 
of altering the biological availability. Nevertheless, 
during the course of this study several important dif-
ferences were detected. Possibilities of variations in 
liquid requirements for the end-point. which could be 
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predicted from particle size analysis and apparent density 
measurements. have to be kept in mind as they affected the 
final hardness of ibuprofen cores. To date all commercial 
ibupr ofen tablets are coated and the ease of coatability. 
mostly relat ed t o friability and hardness. is a crit ical 
parameter in f ormulati on technology. Certainly , s ince dif -
ferent sources led to substantial differences in hardness 
( as a result of higher end-point liquid requirements ) . 
coatability functi on may be affected by slight differences 
between sources. As a consequence. when consistent varia -
tions between two sources can be detected through a solid, 
state preformulation program , key parameters such as den -
sity. crystal size . surface area and crystal s urface 
morphology may be used to predict problems in the formula -
tion behavior. It is appreciated that the conclusions of 
this work d o not advantage one s ource over another. since at 
any moment of the formulati on stage the processing 
parameters can be modified to obtain final products in ac-
cept able ranges , rather those observations underline the 
importance of a strict and detailed physical pharmacy 
profile for materials from different suppliers and suggest 
the usefulness of two validation procedures or two standard 
operating procedures specific to each one of the sources. 
thus avoiding costly unexpected pharmaceutical behavior 
during large scale operations. 
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Table I 
SOURCE AND ORIGIN OF IBUPROFEN 
Name Origin Abbreviation 
Francia Low Density Italy Franl.D 
Francia High Density Italy FranH.D. 
Boots U.S.A. Boots 
Ethyl U.S.A. Eth 
Chemin or India Chem. 
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Table II : 
STARTING FORMULATION 
IBUPROFEN 57 
"' FAST FLOW LACTOSE 36 
"' PLASDONE 6 
"' EXPLOTAB 
"' 
LUBRICANT 
"' 
GRANULATING FLUID (WATER) q.s. 
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Table Ill 
MEAN PARTICLE SIZE < .. cRoHsl 
SOURCE 
FRANCIS LOW D. 
BOOTS 
ETHYL 
CHEMINOR 
FRANCIS HIGH D. 
SRINCKMAN PART ICLE SIZE 
M1cron1sed Water Suspensions 
lurfac•-Numb.,. 
Mean 
3.17 
3 .58 
5 .23 
7.94 
10.54 
ANALYZER 
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Surface-Wtlgtlttd 
..... 
5.03 
6.22 
18.18 
31.07 
38.25 
"' ii> 
2 
Table IV 
SURFACE AREA 
B.E.T. VALUES (SD) in m /gram 
FRANCIS LOW D. 0.76 (0.03) 
FRANCIS HIGH D. 0.86 (0.09) 
ETHYL 0.34 (0.01) 
BOOTS 0.41 (0.03) 
CHEMINOR 0.36 (0.04) 
(•) UNMICRONIZED SAMPLES 
Table V 
MEL TING RANGES 
DIFFERENTIAL SCANNING CALORIMETRY 
SOURCE ONSET (SD) MEL TING POINT (SD) 
CHEMINOR 73.0 (0.2) 75.4 (0.05) 
"' ETHYL 73.2 ( 1.4) 75.6 (0.10) (JI 
BOOTS 73.8 (0.2) 76.1 (0.10) 
F.LOW D. 72.4 (0.1) 7 5.1 (0.10) 
F.HIGH D. 73.4 (0.1) 75.3 (0.10) 
All valuas ara reported in degrees Celsius 
Table VI 
ENTHALPY OF FUSION OF VARIOUS SOURCES (Jig) 
ANALYSIS OF VARIANCE TABLE 
SOURCES 
ERROR 
TOTAL 
df 
4 
16 
20 
SS 
67.63 
57.96 
125.60 
MS 
. ;.91 
3.62 
F 
4 .67 
p 
0.01 
At the 991' confidence l•vel tt'•«• Is • • lgnUlcent difference In AH'• 
o t 3 to 5 J/ g 
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VI 
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Table VII 
LIQUID REQUIREMENTS FOR IBUPROFEN 
GRANULATIONS END-POINT 
SOURCE MEAN VOLUME (SD) IN ML 
ETHYL 27.8 (4.2) 
F.HIGH D. 31.2 (3.4) 
CHEMINOR 31.5 (5. 1) 
BOOTS 44.0 (6.7) 
F.LOW D. 58.2 (2.2) 
Liquid requir ement s for 1 7 5 gm batches 
The average repor ted was obtained trom ell granulations 
( 
Table VIII 
EFFECT OF DIFFERENT SOUR - cS : 
LIQUID REQUIREMENTS FOR GRANULATION END-POINT 
DUNCAN'S MULTIPLE RANGE TEST 
SIGNIFICANCE LEVEL ex • 0 .05 
27.8 
ETHYL 
31.2 
FHIGHD. 
31.5 
CHEM. 
44. 0 58.2 (ML) 
BOOTS FLOWD. 
ANT TWO AVERAGE NOT ~ERLINED BY THE SAllE SEGMENT ARE 
SIG .. ICANTL T DFFERENT 
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Table IX 
WET GRANULES: MOISTURE CONTENT 
ETHYL 
FRANCIS HIGH D. 
CHEMINOR 
BOOTS 
FRANCIS LOW D. 
Loss on cty1no at 65 degrees C 
11 % 
13 % 
18 % 
23 % 
32 % 
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Table X 
HARDNESS LEVELS 
COMPACTION RANGE (KN) 10-15: 
SOURCE FORCE(KN) HARDNESS(Sc) 
ETHYL 10 - 15 19-22 
BOOTS 12-14 22-29 
CHEMIN OR 12-14 12-24 
FRAN.LOW 11-13 19-28 
FRAN.HIGH 10-12 18-25 
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Table XI 
AHlyal1 of Variance for tablet hardneaa 
Ona degree of lreedoom compariaons 
Source di SS MS F p- value 
Among granulations 11 3651.1 331 .9 25 .7 0 .001 
Ethyl Va. Boote 1 127 . 1 - 9.8 0 .025 
Size1 Va. Size3 1 390.1 - 71 .0 0.000 
"' 
Slze2 Va. Size3 1 891 .6 - 69 . 1 0 .000 
.... 
Size1 Va. Size2 1 427 .5 - 33 . 1 0.000 
Within Granulations 66 852 . 1 - 12.9 
S1ze1 : Sieve Frac tion 20/40 ; S1ze3: Sieve Frac ti on BO/Pan 
S1ze2: ibuprofen as 1s 
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Figure 3: 
Scanning Electron Microscopy Photographs of 
Ibuprofen crystals 
I) FLO: Francis Low Density 
II) FHD: Francis High Density 
III) Boots 
I V) Ethyl 
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Figure 4: 
Scanning Electron Microscopy Photographs of 
Ibuprofen crystals 
I) and II) Cherninor 
II) and IV) Ethyl: different batches 
46 
47 
II> 
Cl> 
Figure 5: Typical DSC Endotherm of Ibuprofen 
Sample: Ibuprofen Boots 187327 
Size: 6 . 3000 11g 
Method: 5•c1a1n. 60" to 95•c 
Co•••nt: 100 •L/a11n N2 I Al 1gned Al pan 
73.eJ•c 
119 . 5J/ g 
DSC 
or---~~~~~~-+-.:+-~~~-,,-+~~~~~~~~~-
7& . 13•c 
60 65 70 75 80 85 90 95 
Te•pereture c•c1 
F,~ure 6: X- Ray Diffraction Patterns of Ibuprofen 
Sources 
A. Francis High o. B. Francis Low o. 
c . Cheminor D. Boots E. Ethyl 
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MANUSCRIPT II 
MONITORING CRYSTAL MODIFICATIONS IN SYSTEMS CONTAINING 
IBUPROFEN 
55 
Key words: Ibuprofen: Crystal analysis: Hydrophobic network: 
Intermolecular interactions: Formulation effects. 
SUMMARY 
Qualitative and quantitative crystal analysis . including 
differential scanning calorimetry, X-ray powder diffraction 
and scanning electron microscopy were performed at different 
stages of ibuprofen tablet manufacture obtained at three ._ 
levels of compaction. Melting points and enthalpy of fusi on 
were carefully monitored and compared using statistical 
techniques ( ANOVA and one degree of freedom procedures ). 
Drug - disintegrant interactions were investigated using a 
fractional factorial design. wetting and compaction affected 
the crystal surface as measured by a 0.2 to 8 .6 KJ mole 
decrease in the heat of fusion.and a shift of 2-3 °c in the 
melting point. The differences were too small to suggest the 
existence of enantiotropically or monotropically related 
polymorphs. The results. however. indicated a lattice 
modification of ibuprofen during processing . The initial 
dissolution rates appeared to be inversely related to the 
amounts of ibuprofen in the formulation and the fastest drug 
release was obtained for a 1 / 3 intragranular ratio . 
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INTRODUCTION 
Fundamenoal investigations. especially in the field of 
compaction and weo granulation. have long established that 
pharmaceutical processing can modify some characteristics of 
raw materials in such a way that can be detrimental to the 
overall performance of the final drug product ( Lefevbre et 
al 1986, Chan et al, 1985 ). Monitoring crystal changes has 
become essential in order to optimize many formulations 
(Haleblian et al, 1975). For example, sulfanilamide crystal 
habit was altered as a function of increased compression -
forces or exposure to liquids ( Cruaud et al. 1981 ) and 
physical interactions between ibuprofen and excipients can 
induce eutectic behavior (Gordon et al. 1984; Mura et al. 
1987 ) . The latter does not necessarily mean adverse incom -
patibility but may explain handling difficulties. Many 
pharmaceutical manipulations will affect the crystal habit 
of drug substances and these modifications may have adverse 
consequences on the formulation ( Cruaud et al , 1981 ) or the 
drug bioavailability (Aguiar et al, 1967 ). 
Crystal properties of ibuprofen are known to influence 
the processing behavior ( Romero et al. 1991; Hiestand et al . 
1981 ) . This aspect of ibuprofen formulation is well docu-
mented and it is generally recognized that the drug 
undergoes changes due to processing ( Franz et al. 1986). For 
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example. eutectic behavior has been proposed with some phar -
maceutical excipients ( Gordon et al. 1984 ) and although 
never experimentally proven . surface sintering has been sug -
gested as a theory for rearrangement of crystal lattice 
during compression ( Alhe c et al. 1990 ). 
Nevertheless. very little has been published to support 
evidence of the crystal modifications of ibuprofen. Thus . 
the mechanisms and consequences of such alterations have yet 
to be identified for this particular compound. 
The objectives of this work were to elucidate the 
mechanisms of crystal distortion by which ibuprofen is -
modified during its processing and to investigate these ef -
fects on ·the biopharmaceutical properties of a model 
formulation. 
EXPERIMENTAL 
Materials 
Ibupr ofen USP grade was obtained from the Ethyl Co . 
(LottLH-6-72 ) . Wet granulations containing Fast Flow Lactose 
( Sheffield lot *59009). Povidone (P.V. P.-GAF lotiG-30223A) 
and Explotab ( Edward Mendell lot #l 336 ) were prepared using 
purified water. Granule lubrication was achieved using 
Magnesium stearate ( Fisher Scientific Co. ). The potassium 
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monobasi c phosphate and sodium hydroxide used for dissolu-
tion medium and buffers were obtained from Fisher 
Scientific. All chemicals were of analytical grade. 
Ibuprofen standards for spectrophotometry and differential 
scanning calorimetry ( DSC ) were provided by the Standard 
Divisi on of USP Rockville. MD . 
Methods 
The experimental design consisted of analyzing ibuprofen 
after dry mixing with excipients , wet massing and tableting. -
The model formulation . defined in table I was prepared using 
five process steps presented in table II . The percentage of 
active were 57, 67 , and 77 percent . Mixtures of ibuprofen. 
the diluent , the binder ( 6 percent ) . and the appropriate 
amount of disintegrant were dry mixed for ten minutes. The 
powder was wet granulated in a planetary mixer ( Kitchen 
Aid. model K5 - A. Hobart ) until the end- point , monitored by 
power consumption , was reached. Flow rate o f the granula-
tion liquid remained constant throughout the entire 
experiment. Granules were dried on a tray at 40 °c for 
twelve hours and later mixed with lubricant in a V-blender 
for ten minutes. Lubricated granules were then compressed 
into 350 mg tablets using an instrumented F3 single punch 
press. Three compaction pressures were investigated : low. 
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int ermedi ate 
respecoively ) . 
and high ( averag ing 1.10 and 3 C KN 
At the end of the manufacturing steps I , III , I V and v 
( table II ) . s amples were withdrawn and analyzed by X-Ray 
powder diffraction and scanning electron microscopy ( SEM ) 
photographs. Thermal analysis ( DSC ) was performed on all 
samples ( Kim et al , 1985 ) using a Perkin Elmer. series 7 in-
strumented unit, calibrated with i ndium and interfaced with 
a P 7500 E computer. For whole tablets , the electron micros-
copy photographs were shot at 35 and 80 ° angles on pressed 
and side surfaces, on hor izontal and vertical cross section _ 
of table ts embe dded a nd prepared according to a method 
describe d by Hess , ( 1978 ) . 
Cry stal Packing 
The unit cel l of ibuprofen crystal was analyzed using 
the mo l ecular mode l ing software. The coordinates of single 
X- ray reflection data was obtained from the literature 
(McConne ll , 1974 ) and t he molecular arrangement of a cryst al 
lattice , simulated on thi s program. 
Comparative Analysis 
I n an effort to mimic the effect of processing, 
ibuprofen and physical mixtures of the formulation were 
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gr ound thor oughly for t en minute s in a mortar or melted at a 
temperature above 80 °c and recry stallized u pon coo ling at 
r oom t e mperature ( RT ) . Di fferential scanning calorimetry was 
further performed on the samples and their thermal profiles 
compared t o those of pure and formulated ibuprofen . 
Additionally. ibuprofen hygroscopicity was meas ured after 
storage at 35 °c and 85% relative humidity ( RH ) . Karl Fisher 
analysis was performed at regular time intervals on 100 mg 
samples exposed to humidity. 
Biopharmaceutical Properties 
The dissolution apparatus used a paddle rotating at 50 
RPM in a USP phosphate buffer at pH 7 . 4 and a temperature of 
37 °c. This method using a six vessel dissolution apparatus 
(Vankel ) had been shown to discriminate between various 
ibuprofen formulations ( Romero et al , 1988 ) . An ultra-violet 
spectrophotometer wa s used to determine the concentration of 
ibuprofen at 264 nm in the dissolution fluid. For low 
ibuprofen concentrations. the percentage dissolved was also 
calculated f r om measurements obtained at 220 nm. 
Statistical Analysis 
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All results were analyzed statistically using an 
analys is of variance at the 99% confidence level to deter -
mine differences between enthalpy of fusion and melting 
ranges . Sums of squares were calculated to perform one de-
gree of freedom comparisons using orthogonal contrasts. 
These tests allowed the investigation of pure compaction ef -
fect on the thermal parameters . A restricted fracti onal 
factorial design was used to test the effects of 
drug disintegrant interactions. The independent variables 
were amounts of active and the concentration of ex -
tragranular disintegrant. All factors had three levels . In _ 
the interpretation of the data greatest weight was placed on 
a ny effects on dissolution. 
RESULTS AND DISCUSSION 
Crystal Packing 
The single crystal unit cell for the racemate included 
four molecul es: two R(-) and two S(+) isomers. two central 
hydrogen bonds between the carboxyl ic f unctions of 
dextrorotary and levorotary molecul es ( Fig . 1). In addition 
figure 2 shows the juxtaposition of eight crystal unit 
cells. The hydrogen bonds between cells could be identified. 
Each inte r molecular interaction was shared betwe en fou r 
other cells as favored by the preferential positioning of 
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R(-) and S ( ~) molecules . Except for the top - left cell 
retained f or baseline comparison. each unit has been cleared 
of the molecules not involved in the intercellular interac-
tions. The resulting effect is the delimitation of a plane. 
on which intermolecular distances are most likely to be af -
fected during tangential stress. Thus this eight cell system 
may explain the observed lattice weakness. 
The mass fraction of water obtained by the Karl - Fisher 
technic , averaged ( 0.063% + 1- 0.001 ) and (0.55% + - 0.004 ) 
before and after exposure to humidity respectively. This 
analysis confirmed that although the moisture increased ten _ 
fold after exposure to 85% relative humidity for 76 hours . 
it did not.exceed 0.55% possibly concentrating at the sur -
face since ibuprofen does not include crystallization water. 
This amount of moisture. was defined by Alhec and Zografi 
(Alhec et al, 1990 ) as plasticization or molecular mobility. 
Thermal Analys is 
Thermal analysis of ibuprofen indicated that only com-
paction or grinding of the physical mixture affected the 
melting point and the heat of fusion (table III ) . All 
parameters were compared at the 99% confidence level. 
Furthermore. the enthalpy of fusion decreased progressively 
to as low as 18.l KJ / mole during the tablet manufacture. If 
the assumption that a pure equilibrium exists at the melting 
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point ( Tm ) is valid. then the changes are probably ~ndica-
tive of enthalpic modifications ( weaker intermolecular 
interactions ) at the crystal surface before compression. 
then : 
t.G 
-
t.H - Tm . t.S equation 1 
at Tm the melting po int. t he free energy t.G sh ould 
equal zero. with t.Hf the enthalpy of fusion of the sample, 
t.t.Hf the enthalpy loss and t.Tm the melting decrease. 
t.G O and t.H Tm . t.S equation 2 
Mixing with excipients and process ing are the combina-
tion factors responsible f or the enthalpy drop. Table I V 
summarizes the statistical analysis of thermodynamic 
parameters . All enthalpy of fusion were significantly dif -
ferent as determined by the F test ( see table IV ) . The 
magnitude of the shift depended on the stage of processing. 
The orthogonal contrasts Ll , L2.L3 were found statistically 
significant. Compression had an effect on the enthalpy of 
fusion and ibuprofen in lower strength formulation appeared 
to be less sensitive than in higher strength tablets . The 
heat of fusion for ibuprofen was less affected in granules 
than in tablets. 
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X- Ray Crystallography 
In figure 3 the X-Ray diffraction patterns of pure 
ibuprofen dry granules and ground tablets indicated crys-
tal changes of ibuprofen during pharmaceutical 
manipulations: dilution with excipients only decreased the 
intensity of the diffractogram. Wet granulation , h owever. 
induced a slight rearrangement of the cr··stal lattice . At 
low angles of the spectrum , the 12.2° deflect i on peak com-
pletely d isappeared leaving an amorphous region. No further 
changes were visible on the X-ray diffraction pattern after -
compaction. 
Scanning Electron Microscopy 
In order to complement results of the thermal analysis , 
qualitative observations were performed by SEM. 
Morphological changes from pure to formulated ibuprofen were 
visible at the XlOOO magnification as shown on figure 4. On 
the tablets. the crystals are visible but the particle 
boundaries are not detectable (indicating cold bonding or 
fusion at the surface). Thus , an ibuprofen network appeared 
to result from sintering of the ibuprofen crystals during 
processing. Cross sections of tablets showed a film of PVP 
( light membrane ) covering packs of ibuprofen crystals 
( dark). Some starch glycolate particles are also visible. 
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The macroscopic observation of SEM phocographs confirmed the 
crystal disorder suggested by chermal analysis : the wet 
granulation process induc ed the lattice fragilization and 
upon compaction . further crystal disrupti on occurred with a 
poss ible consolidation of the hydrophobic matrix . The dis -
integration and dissolution analysis confirmed that the 
ibuprofen network was indeed hydrophobic. When two ibuprofen 
particles are in contact. within a formulation . thermal 
properties have already been disturbed; upon compaction. 
enough mechanical ener gy is provided to induce cold welding 
or sintering of the crystalline envelopes of ibuprofen as _ 
visualized on these S.E.M photographs. 
Effect of Process ing 
The decrease in Tm averaged a statistically significant 
2-3 °c upon compaction. ATm was not proportional to the com-
pression as indicated by paired t tests (fig.5 ) . The 
reported values of compaction are arithmetic means of upper 
punch compression forces recorded on the instrumented press. 
The e n thalpy decrease AAHf was defined as t he difference be-
tween the heat of fusion of pure ibuprofen and the energy of 
fusion of the formulated ibuprofen . AAHf was indicative of 
the extent of some crystal modifications. The effects of 
compaction and low ibuprofen strength on the thermodynamic 
parameter have been found statistically significant ( table 
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I V). I n f i gure 6 f or all Sorengths studied t he enthalpy l oss 
inc rease d a nd stabilized at a plateau value . Low conc ent ra -
oio n s of ibuprofen seemed t o be less sensitive t o me chanical 
stre s s . The latter. however. had the highest shif t before 
tableting. These results are conclusive of two opposite ef -
fects of a low active excipient rati o during tablet 
manufacturing. Similar effects had been previously sug ge s ted 
by a study on the pharmaceutical processing of sulfanilamide 
( Cruaud et al. 1981 ) . 
Dissolution Studies 
The dissolution profiles of ibuprofen cores also ex-
hibited similar trends , as seen in figures 7 - 8 . Low 
ibuprofen content led to cores with fast dissolution rates 
as compared to higher strength dosage forms. Although the 
data suggested that initial drug release rates might be re -
lated to the extent of the ibuprofen network ( table V) . any 
correlation was insignificant because of the limited number 
of points. The crystal modi fication of ibuprofen created the 
surface hydrophobic network within the tablet that may be 
quantified by AAHf. The latter seemed to be the limiting 
factor of drug release . The dissolution efficiency was op-
timal for the lowest amount of ibuprofen and the highest 
concentration of disintegrant (3% ) in the 1 / 3 intragranular 
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ratio. Formulati on with 100% ex,ra or intragranular disin -
oegrant had l ower dissolution efficiencies than did 
formulati on c ombining extra ' intragranular disintegrant at 
the same c onc entrati on.This might be another evidence of the 
existence o f the hydrophobic network. 
CONCLUSIONS 
The crystal packing of ibuprofen occurs with a preferen-
tial orientation in which a weak plane has been identified 
as probably responsible for the crystal modifications during _ 
compaction. 
Pharmaceutical processing does alter the crystal habit 
of ibuprofen ( not its internal structure ) in a stepwise man -
ner. We identified three progressive mechanisms: 
Mixing with excipients: destabilization and fragilization of 
intermolecular interactions, wet granulation: distribution 
of water in the amor phous regions. Both mechanisms account 
for a drop of 4.1 KJ / mol e in the enthalpy of fusion and 
predispose the ibuprofen to col d welding. Compaction: brings 
the enthal py decr ease to another 6.2 to 8.6 KJ / mole and 
provides enough energy to catalyze sintering as observed on 
the scanning electron microscope. In addition to lattice 
rearrangement , the resulting ibuprofen network is 
hydrophobic and could be the limiting factor of drug dis-
solution. As a consequence formulators must be extremely 
68 
cautious vhen increasing ibuprofen concent ration in t ablet 
formulation. 
REFERENCES 
A. J . Aguiar , J . Krc, A. W. Kinte l and J .C . Samyn 
"Effect of Polymorphism on the Absorption of 
Chl oramphenicol from Chl o ramphenicol Palmitate " 
J.Pharm.Sci . , 56 (7), pp 847 - 853. 1967 
C . Alhec and G. Zografi 
J . F . 
H. K. 
"The Molecular Basis of Moisture Effects on Drugs 
in the Solid State." 
Accepted Int . .r.Pharm . , 1991 
McConnell 
"2 -( 4-Isobutyl Pheny l ) Propionic Acid. 
Cr~:;it.S:truQ:!; . CQmm . 3 , pp 73 - 75. 1974 
Chan and E . K. Doelker 
"Polymor phic Transformation of Some Drugs under 
Compr ession" 
I.llll.E . 11 ( 2&3 )' pp 315 -332. 1985 
O. Cruaud , D. Duchene, F. Puisieux, A. Chauvet, J . Masse 
"Etude des Transformations Poly morphiques du 
Sulfanilamide au cours de la Fabrication des 
Comprimes" 
.r . Pham . Belg. , 36 ( 1 ). pp 15 -20, 1981 
Robert . J . Franz , 
69 
"Stable High Dose. Hi gh Bulk Density Ibuprofen 
Granulati ons for Tablet and Capsule Manufacturing" 
U.S . Patent 4 , 609.675 Sept. 2. 1986 
P.E. Gordon , C . L . Van.Koevering , and D.J. Reits 
"Utilization of DSC in the Compatibilty Screening 
of Ibupr ofen with Stearate Lubricants and 
Construction of Phase Diagrams " 
Int.J . Pharm. 21 : 99-105. 1984 
John K. Haleblian 
"Characterization of Habits and Crystalline 
Modifications of Solids and their Pharmaceutical 
Applicati ons " 
J.Pharm.Sci 64 ( 8 ), pp 1269-1288. 1975 
H. Hess 
"Tablets Under the Microscope. " 
Pharm.Tech., pp 36- 50 , Sept. 1978 
E . N. Hiestand , G.E . Amidon , D. P. Smith , and B.D . Tiffany 
"Mechanical Property Changes of Compacts from 
Various Rates of Crystallization of the Solid. 
Proc.Techn.Prog.Int.Powd.Bulk Solids Handling 
Proc. , Rosemont. IL 1981 
H. Kwon Kim , M. J. Franck , and N. L . Henderson 
"Application of DSC to the Study of Solid Drug 
Dispersion " J.Pharm.Sci .. 74 ( 3 ), pp 283-289 . March 
1985 
C . Lefevbre, A. M. Guyot - Hermann , M. Draguet , R . Bonde , 
70 
and J.C. Guyot 
"Polymorphic Transition of Carbamazepine during 
Grinding and Compression· 
rilll.E.... 12(11&13) , pp 1913-1927. 1986 
P. Mura , A. Liguori, G. Bramanti , and L. Poggi 
"Phase Equilibria , Crystallinity and Dissolution 
Rates of Ibuprofen-PEG 20.000 Solid Dispersions · 
Il Farrnaco-Ed . Pr., Vol. 42. Fasc. 6. pp 157-164 , 
1987 
A. J. Romero , L.T . Grady and C. T . Rhodes 
"Dissolut ion Testing of Ibuprofen Tablets " 
D. D.I.P. , 14 ( 11 ). pp 1429-1457 , 1988 
A. J . Romero , G. Lukas, C. T . Rhodes 
"Influence of Drug Sources on the Processing and 
the Biopharmaceutical Properties of High Dose 
Ibuprofen Formulations.· 
Pharm.Acta Rely .. 66(2 ), 34-43 , 1991 
Aknowledgements 
This work was supported by Ciba-Geigy Corporation 
We aknowledge, with gratitude the help of Dr . Franck Clarke , 
Basic Research at Ciba- Geigy who made invaluable contribu-
tions to the success of this project 
71 
Teble I: Formuletlona UHd In thla Study 
Ingredient Amount In % 
Ibuprofen 57 67 11 
Feat Flow LectoH 36 26 16 
P.Y.P. 6 6 6 
Ilg Steerete 1 1 
% Ne Sterch Glycolete • 1 2 3 1 2 3 1 2 3 
-'1 
"' 
•D11tails on th11 
111• lntragr11nul11r ratio 1 1/2 1/3 1 1/2 1/3 1 1/2 1/3 
Purified Weter q.1. q.1. q.1. 
All ay1tema contelned 1 % of lntregrenuler dl1lntegrant 
. ' 
-<I 
Vl 
Table I: Experimental llethodology 
ProceHlng 
Dry ••Int (V-Blender) 1 O mlnutea 
(Ibuprofen, LactoH, Explotab, PVP) 
Wet Granulatlon 
(llonltored by power conaumptlon) 
12 how tray drying at 40 C 
•xllllg (V-Blender) 10 mlnutH 
(QranulH, Explotab, Lubricant) 
Compaction 
Stepa 
II 
HI 
IV 
v 
Analyala 
DSC, SEii, X 
DSC, SEii, X 
DSC, SEii, X 
DSC, SEii, X 
DSC, SEii, X 
DIHolutlon 
Hardneaa 
DSC: clfferentlal acannlng calorlmetry, SEii: acannlng electron 
.icroacopy, X: X-ray cryatallography, 
' . 
T8ble •: Thermal Analyal• of Ibuprofen 
II.Pt.( SD) AH (SD) AS [J.G - . 'K ] 
[oC) [KJ/mole) 
IBUPROFEN 
Pwe 77.7(0.6) 25.7(0.53) 0.35 
Ground 76.8(0.2) 23.7(0.93) 0.33 
Melted(•) 76.9(0.,) 23.0(0.91) 0.11 
RH(••) 77.2(0.3) 25.6(0.06) 0.35 
~ Phyalcal 
ti> Mixture 77., - 21.0 - 0.29 
Ground 75.3 - 18.1 - 0.25 
Granule• 77.3(0.2) 21.9(1.29): 0.30 
Tablet• 75.2(0.9) 18.2(1.71) 0.25 
(•) recryatalllzed at RT, (••) 76 hour• at 85 " RH 
(., atellotlNllr alllllf!CMI ...,.,....,. _.,... lo -· ._ .... 
' ' 
Table IV: ANALYSIS OF VARIANCE (ENTHALPY OF FUSION) 
One degrH of Freedom comparisons 
SOURCE DF SS llS F F 
o .0 1.1,4t 
Among 
Formulations 9 •365.7 •B5.1 13.62 7.3 
• L 1 KN Vs. NoKN 1 - - 948 
-.;i 
L.Z Low KN VS 
• (JI High/Reg KN 1 - - 429 
£3 A-57% Vs. 
C-67% or 
• E-77% 1 - - 19.8 
Within 
Formulations 33 1157.3 35.6 
(•) indicates a significant difference (99% confidence level) 
' ' 
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Figure 4: Identification of the Ibuprofen network 
Electron microscopy photographs of 
A) Ibuprofen, Bl grHulea, C) tablets: 
C1,C2: preaHd surface, C3: aide walls 
C4: vertlcal croaa section 
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Figure 6: Effect of Compression Forces 
on the Enthalpy Parameter 
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Figure 8 : DluolutlH of Ibuprofen C.rH 
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( MANUSCRIPT III 
AN EVALUATION OF IBUPROFEN BIOINVERSION BY SIMULATION 
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INTRODUCTION 
In an e ffort to formulate the pharmacologically active 
enantiomer of ibuprofen into a solid ora l dosage form. we 
examined the literature regarding investigations of 
stereoselective pharmacokinetics of this arylpropionic acid . 
Early reports (1) indicated that urinary ibuprofen metabo-
lites were essentially all dextro-rotary (S enantiomer ) 
following administration of 
Sensitivity of stereoselective 
separations have improved and it 
the racemate in man. 
assays and enanti omeric 
is generally recognized . 
that there is an enzyme catalyzed inversion of the inactive 
R enantiomer into the therapeutically active S enantiomer 
(2.3) . Bioinversion of the R to the S enanti omer has been 
suggested to occur either presystemically ( 4 , 5) and or sys-
temically ( 6 ) . Also. differences in the fraction of R 
inverted int o Shave been reported (7. 8 ). To date only four 
studies have involved the administration of a pure ibuprofen 
enanti omer t o man (6, 9 ). Using the pharmacokineti c model 
proposed by Jamali et al . ( 5 ), we simulated (-)-R- and 
(+)-S- ibuprofen plasma concentrations following oral ad -
ministration of (+)-S- ibuprofen, (-)-R-ibuprofen , or the 
racemate . Simulated and literature values for area under 
the plasma concentration- time curves ( AUC ) were used to com-
pare ratios of SI R for different cases of the model and for 
87 
comparison of different methods calculating fraccion of R 
inverced to S. 
METHODS 
Simulations 
The one-compartment model proposed by Jamali et al . ( 5 ) 
was used for all simulations of ibuprofen enantiomer plasma 
concentrations. This model (Fig. 1) assumes first-order 
processes for absorption and elimination for both R and S 
enantiomers , as well as for the bioinversion of the R to the . 
S enantiomer. This model appears to have been designed such 
that total elimination of R. by bioinversion and non-
bioinversion routes , should be equal to elimination of S. 
The literature , however, supports a faster apparent elimina-
tion for the R isomer ( 6-8 ). The racemate dose was assumed 
to be 200 mg of (-)-R-ibuprofen and 200 mg of (+)- S-
ibuprofen enantiomer. Pharmacokinetic parameters similiar 
to those used by Jamali et al. ( 5) were incorporated. 
Volumes of distribution (Vd) were 10 L for each enantiomer. 
Absorption rate constants ( kar.kas ) and elimination rate 
constants (kr , ks) for both enantiomers were 1.0 and 
0.34 - 1 hr , respectively . The four cases of presystemic 
(kip) and / or systemic ( kic ) bioinversion reported by Jamali 
et al. ( 5 ) were reproduced as follows: 1 ) kip=l.5 and kic=O 
hr - 1 , 2) kip=l.O and kic =0.08 hr- 1 , 3) kip=0.5 and 
88 
kic-0.15hr- 1 . and 4 ) kip-0 and kic -0.225 hr - 1 . Numerical 
simulation of the model was performed with the Stella 
simulation software ( 10 ), using Euler ' s method with a time 
step of 0.01 hr. The apparent terminal elimination rate 
constants for the R and S ibuprofen enantiomers ( App kr and 
App ks) were estimated from simulated plasma concentrations. 
The area under the simulated plasma concentration-time 
profile from time zero to 24 hr after start of dose. AUC (0-
24) , was calculated for both enantiomers. These simulated 
AUC's were used to calculate an S I R AUC ratio. The AUC 's 
from these simulations were also used to compare different . 
methods of calculation the fraction of the R enantiomer in-
verted to the S enantiomer following oral administration. 
In additon. literature values for AUC of Rand S (4.6-9,11) 
were used to calculate an SI R AUC ratio and assess different 
methods for estimating fractions inverted. 
Calculation of Fraction Inverted 
For calculations of fraction of ibuporfen inverted in 
the body. it was assumed that both enantiomers have similiar 
absorption and disposition parameters. Also , it was assumed 
that oral administration of racemate was similar to oral ad-
ministration of equal amounts of S and R ibuprofen 
enantiomers. These assuptions are recognized as potential 
limitiations of the calcualtion method but have been used by 
several authors (5-9, 12 , 13 ) . 
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The relationship assumed was : 
( AUC of s after racemate ) - ( AUC of s after S) - ( AUC of S 
after R) Equation 1 
where dose of racemate - dose of s - dose of R. and the dose 
of R and S are equal. 
The fraction of R inverted to S ( Fr s ) may be approximated 
by : 
Fr- >S = ( AUC of s after R) / ( AUC of s after S) 
for equal doses of R and S. 
Equation 2 
Substitution Equation into Equation 2 , additional equa-
tions for Fr s may be derived: 
Fr - >s - (( AUC of S after racemate )-( AUC of S after S)) i ( AUC 
of S after S ) Equation 3 
where dose of recemate 2•dose of S:and , 
Fr s = ( AUC of S after R) / (( AUC of S after Racemate )-( AUC 
of S after R)) Equation 4 
where dose of racemate 2*dose of R. 
Based on the previous assumptions of identical absorption 
and disposition for both enantiomers , it may be possible to 
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approximate fraction inverted in the body following oral ad -
ministration of the R and S enantiomers. the racemate and S 
enantiomer, or the racemate and R enantiomer. 
In addition one can estimate the contribution of the 
chiral bioinversion to the plasma levels of the therapeuti -
cally active isomer. Rather than calculating the fraction 
of R converted to S ( Equation 2-4). an alternate method of 
looking at bioinversion is by estimation of the fraction of 
S which is inverted from R ( Fs- >r) for a dose of racemate. 
This may be approximated by the following equation: 
FS- >r ( AUG of S after R) / (AUC of S after racemate ) 
Equation 5 
where dose of racemate 2* dose of R(-). 
Additional variations of Equation 5 are also possible if one 
assumes the relationship in Equation 1 to be valid. 
RESULTS AND DISCUSSION 
Simulated ( -)-R- and (+)-S-ibuprofen enantiomer plasma 
concentration-time profiles and t he corresponding S I R plasma 
concentration ratios appeared to be identical to that 
reported Jamali et al. (5) for the four different cases of 
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presystemic and or systemic bioinversion following ad-
ministration of 400 mg of racemate as 200 mg each of R and S 
enantiomers Simulations of the S R AUC ratios. following 
administrati on of the racemate. ranged from a value of 4.0 
for a presystemic-only bioinversion ( Sim #1. Table I) to 
1 .66 for systemic-only bioinversion ( Sim *4. Table I ) . 
Simulati ons of the S R AUC ratios. for administration of 200 
mg of the R enantiomer only, ranged from a value of 1. 5 f or 
a presystemic-only bi oinversion ( Sim #5 . Table I ) to 0.66 
for systemic-only bioinversion ( Sim ~s. Table I ). 
Calculati ons SI R AUC ratios from literature reports of AUC ' s . 
of R and S enanti omers following administration of the 
racemate averaged 1.53±0.20 ( average±sd ) . while S / R AUC 
ratios following administration of the R enantiomer were 
found to be 0.50±0.09 ( Table II ) . Thus. these simulations 
support a conclusion of systemic bioinversion in man s ince 
they appear to be in good agreement with the literature 
data. Different conclusions by Jamali et al . (4,5) . based 
on use of a plasma concentration SI R ratio . may be due to 
increased variability in plasma concentrations R and S enan -
tiomers . Since the emphasis of that ratio was placed toward 
the end of the sampling period when plasma concentrations 
were relatively low ( 4,5 ), a greater error in calculation of 
the plasma concentration SI R rati o could have arisen from 
assay variability. It is speculated that calculations S and 
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R AUG'S. for the S R AUG ratio. are not as susceptible to 
the same degree of such error . 
Agreement of simulated S R AUG ratios with literature 
values does not necessarily support the hypothesis of 
sytemic bioinversion , since the mode proposed by Jamali e t 
al. ( 5 ) may be questioned. The mode ( Fig . 1 ) appears to 
have been designed to demonstrate similiar elimination for R 
and S. The sum total of R is ( kr - ki c)Tkic. which equals ks. 
This creates some confusion since elimination of R by non -
bioinversion routes and elimination of S could be 
comparable. However , elimination of R by processes other 
than bioinversion was adjusted by the systemic bioinversion 
rate constant ( i.e . kr-kic, Fig. 1 ), according to the model 
defined by Jamali et al. (5). It was assumed that this 
model was derived to demonstrate similiar ' apparent ' 
elimination rate constants for both R and S ( App kr and App 
ks , Table I ), which holds true for the presystemic-only 
bioinversion case (Sim # l and Sim *5. Table. I ) . However. 
as the model is admusted toward systemic-only bioinversion , 
the apparent eliminat i on rate constant for S , determined 
from simulated plasma concentrations (App ks ) , decreases. 
ne suggested modification of the model is not to adjust non-
b i oinversion elimination of R by the changes in kic . Other 
model modifications are a l so possible , such as suggested 
from the studies by Ahn et al. in the dog ( 12 ) . from which 
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it may be speculated that the rate and extent of bioinver -
sion decreases with increasing amounts of (+)-S-ibuprofen. 
Thus. a model incorporating saturable enzymatic inversion 
may prove to be a more correct model. We also appreciate 
the fact that gastro-intestinal membranes of different 
animal species contain the enzymatic system responsible for 
the stereospecific inversion. Therefore. presystemic bioin-
version. if any. could be formulation dependent. 
An assessment of the fraction of R inverted to S (Fr- >s) 
was based on calculations using Equations 2-4 for simula-
tions and literature values for AUC ' s of the S enantiomer . • 
following administration of S and R. S and racemate. or R 
based on the same model ( Sim #9, Table I ). Using Equati on 
2. and the results for simulation of the R and S enan-
tiomers, the 
pre systemic-only 
simulation. It 
fraction inverted ranged from 0.6 for 
simulation to 0.66 for systemic-only 
must be noted that Jamali et al. ( 5 ) chose 
parameters for presystemic and systemic bioinversion which 
would approximate a fraction inverted of 0 . 6 , which i s con-
sistent with the data of Lee et al. (8). Assessment of 
Geisslinger et al . ' s data ( 7 ), using Equation 2. indicates 
the fraction of R inverted to S was 0.48 ( Table II ), al-
though these autors who reported a fraction inverted of 0.33 
did not indicate their exact mathematical operation . 
Calculations of Fr - >S using Equation 2 ranged from 0.36 to 
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0.64 f or all literature values o f AUC after S for ad -
ministration of the R and S enantiomers ( Table II ). 
Fractions inverted calculated for Equations 3 using litera-
ture values ranged form 0.25 to 0.74. while Equation 4 
yielded values of Fr- >s ranging from 0.51 to 0.96 . It is 
important to note that when AUC data was not available for a 
particular enantiomer, data from Lee et al. ( 8 ) or Cox et al 
(6 ) were used after normalization for dose. Since dif -
ferences were found for literature values when fraction 
inverted was calculated using Equations 2-4. it might be 
concluded that the relationship described in Equation is. 
not a rigorous as originally assumed. In the four studies 
involving administration of (- ) -R - ibuprofen. the AUC of S 
and R averaged 1 / 2 of the AUC of Rafter R (49 . 7%). Using 
Equation 5 , we calculated that after oral administration of 
the racemic mixture. (+)-S-ibuprofen bioinverted from ( - ) -R -
ibuprofen averaged 38 . 5% of the total ( T) -S-ibuprofen in the 
systemic circulation. 
CONCLUS I ONS 
The model presented by Jamali et al. (5 ) , for bioinver-
sion of ibuprofen after administration of a racemic mixture , 
was reviewed and found to be more indicative of systemic 
bioinversion when the AUC SI R ratio was taken into account 
and compared to literature values. Results of simulations 
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with this model demonstrate no diffenece between equaoions 
fo r Fr - •s. based on AUC of S following administration of R 
and S. racemate and S. or racemate and R. for ohe four cases 
of presystemic and or syst emi c bi oinversi on inve stigated. 
However. comparison of results of Equati ons 2-4 using 
literature data differ such that it does not appear that the 
relationships assumed f or the model h old true under all 
dosing situations . Calculations Fr - s ( Equations 2-4 ) using 
literature data averaged 0.52 overall. 
We estimated that after racemate oral administration. 
1 / 3 of the total (+)-S-ibuprofen ~ n the plasma is derived . 
from the inversion of (-)-R- ibuprofen. Possibly a 150 mg 
dose of (~)-S-ibuprofen will be bioequivalent to a 200 mg 
dose of rac-ibuprofen after oral administration . Whether or 
not the formulation of the active stereoisomer is a 
therapeutic improvement can be still argued and other phar -
maceuticial characteristics of the drug must be considered. 
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<D 
<D 
Dosing · 
Race male 
Racemale 
Race male 
Race male 
Ronly 
A only 
A only 
A only 
• Dose of A .. 200 mg 
Dose ol S • 200 mg 
1.5 
1.0 
0.5 
0 .0 
Table I 
S1mulat10n Paramelers and Rosulls lof 81omve1s1on ol Ibuprofen, 
Based on lhe Model ol Jamah el al. (5) 
w11h Cak:ulalions ol AUC SIA Aalio and Fraction ol R lnvef1ed lo S (fr->s) 
0.0 
0.08 
0.15 
0.225 
0.341 
0 .341 
0.341 
0.341 
0.341 
0.317 
0.305 
0.296 
23.52 
29.40 
39.20 
58.80 
35.28 
36.30 
36.84 
38.78 
1.501 
1.23 
0.94 
0.66 
Addilional Parameters used tor all simulations 
A S 
Dose of Racemale • 200 mg of A and S each ka. 1.0 1.0 hr ... · 1 
k • 0.34 0.34 hr• -1 
Vd • 10 10 L 
,_, 
0 
0 
l .iblu II 
Al.JC Values in Man alttH Adm1rns1ia1ion of lnd1vldual lbuprnhm l:nanhomurs or Aacama1a 
wllh Cak:ulalions ol Al.JC SIA Aallo, F1ac11on ol A Inverted 10 S (Fr ·>S), and Frac11on ol S lnve11ed F1om A (fs<- r) 
-· Geissl"-
7 PO 600 89.8 57.0 1.58 0.34 0.56 0.36 
Cox 6 PO 600 91 .0 61 .0 1.49 • 0.30 0 .63 0.38 
Cox 6 IV 600 89.0 59.0 1.51 • 0.27 0.51 0 34 
Cox 11 PO 400 58 0 42.0 1.38 • 0.25 .6 0 .67 " 0.40 
Cox 11 PO 400 580 50.0 1.16 • 0.25 "0.67 "0.40 
Jama' 4 PO 600 106.9 74.2 1.44 ' 0.53 • 0.7 1 • 0.42 
Jamai 4 PO 600 121 .7 73.9 1.65 • 0.74 • 0.58 • 0 .37 
Jamai 4 PO 600 90.8 56.9 1.60 • 0.30 • 0 96 • 0.49 
Jamai 4 PO 600 100.2 51.5 1.95 • 0.44 • 0.80 • 0.44 
Average (OveraU) • 0 ·I ' 0.38 0 70 0 41 
SO (Overall\ - 0 10 0 16 0 IL 0.05 
Average (True"") - 0.56 0.36 0.64 0.39 
sp tlrue .. ) • 0 11 0 03 0 15 0 05 
Avg ol Eqns 2-4. 0.52 
Ava of Eans 2 ·4 llrue""I • 0.55 
•compared lo lee dala (8) tor admimslralion ol S, normalized for dose 
6 compared Jo Cox data (6) for adm1nistralion ol A. normalized tor dose 
•compared 10 lee data (8) tor adrmnis11auon ol A. normalized lor dose 
•• al parameters used in 1he equation were obtained from individual stud10s 
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MANUSCRIPT IV 
APPROACHES TO STEREOSPECIFIC PREFOR.MULATION OF IBUPROFEN 
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Abstract 
In an effort to formulate the pharmacologically active 
ibuprofen isomer ((- )- S- ibupro fen ) into a solid oral dosage 
form , preformulation studies were performed on both the 
racemate and this stereoisomer of ibuprofen . Results of the 
respective physical pharmacy profiles were compared to 
predict the pharmaceutical behavior of the S( - ) ibuprofen 
compound. The enantiomer was more soluble than the racemate 
in aqueous media but exhibited l ower intrinsic dissolution 
rates. as would be expected from the very small specific . 
surface area. This characterisitic could be a limiting step 
in the formulation of the optical isomer although less 
energy was required for the solution of S(+) ibuprofen . On 
this crystal , there was ten times more moisture layered at 
the surface and comparative thermal analysis indicated that 
for both compounds a l oss in crystallinity occured upon 
grinding . Properties in the solid state of S(+) ibuprofen 
included higher density and excellent flowability as com -
pared to the racemate. 
INTRODUCTION 
Recently extensive emphasis has been given to the 
stereospecific nature of drug disposition in the context of 
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drug development. Re gu l ato r y bodies in Eur ope already r e com-
mend che use of s tereospecific assays when a r a c emate is 
fo r mulaced ( 1 ). In this case. when the chi r al s ynthes i s i s 
p oss ible. the f o rmulati on of pure active enantiomer s also 
becomes a priority for research and devel opment. Thu s . f or 
drug candidates in the development pipeline stereospecific 
considerations are critical . For drug products al r eady 
marketed as racemates. the study of their optical i somers 
might present a different set of problems ( 2 ) . 
The use of an enantiomer as part of a solution for c om-
mon pharmaceutical problems is not new . In the early . 
seventies. formulators at Wyeth had described the advantages 
of using the pure optical isomer of a cytotoxic agent to 
overcome a solubility problem (3). The differences in 
physico- chemical properties between racemic and enantiomer 
have been known and studied for a long time ; s olid state 
properties , crystal structures and the effect o f isomeric 
purity on phase solubilities ( 4-6 ) have been investigated. 
Recently the effect of chiral asymmetry on crystal 
properties was reviewed and it was concluded that for such 
compounds. biopharmaceutical characteristics must be care-
fully monitored ( 7 ). 
Ibuprofen is administered as a racemate and is one of 50 
compounds for which detailed stereospecif ic pharmacokinetics 
have been reported. Properties in solution and the solid 
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state have been documented in the literature and conven -
tional preformulation programs have been applied to the 
study of this antiinflammatory agent ( 8). It is now 
generally recognized that formulating ibuprofen is difficult 
and relies mainly on the expertise of the formulator . Its 
low solubility in aqueous media at low pHs as well as its 
poor handling properties contribute to its tedious process -
ing. S(+) ibuprofen , the biologically active isomer of 
ibuprofen, is now available in large scale quantities 
through economically viable chemical synthesis and the ob-
jectives of this study are to draw a preformulation profile . 
for this enantiomer. investigate the feasibility of a con-
ventional formulation and compare this stereoisomer to the 
racemate currently used. 
EXPERIMENTAL 
MATERIALS 
Rae-ibuprofen (lot# LH6 - 72 ) and (+)-S-ibuprofen (lot¥ 
AC-lR) were obtained from the Ethyl Co., Baton Rouge , LA. 
Monobasic potassium phosphate and sodium hydroxide from the 
Fisher Scientific Company, were of analytical grade. 
METHODS 
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Analvtical: all quantitative determinations in solut i on 
were performed using an ultra violet spectrophotometer 
(Hewlett Packard 8450) at 264 and 220 nanometer wavelengths. 
Intrinsic Dissolution Rate ( IDR ) 
The procedure desribed by Woods ~ ( 9 ) was used to 
determine the intrinsic dissolution rates. A modified Woods 
apparatus , designed by Ciba-Geigy researchers ( fig. 1 ) was 
used. One gram of sample powder was weighted in the die and 
precompressed at 500 lbs with a Carver hydraulic press. 
After cleaning the exposed surface the compact was 
recompressed at 1000 lbs for a dwell time of 5 seconds. The 
rotating disk assembly was immersed in 500 ml of USP simu-
lated intestinal fluid ( SIF ) at 37 + / - 0.8 °c and rotated 
at 100 rpm. The sampling regimen . included 
2.5 , 10.15.20 , 25 . 30 and 35 minute time points. Sample volume 
was 4 cm3 . withdrawn with micro-syringes and replaced with 
the same volume of SIF at 37°c. All samples were passed 
through a 0.45 um cellulose acetate filter before analysis. 
Amounts of drug dissolved were plotted versus time and the 
slope of the straight line portion was divided by the area 
of the pellet ( A-1.281 cm2 ) to yield the intrinsic dissolu-
tion rates in mg.sec-l cm-2 . 
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Solubility and Heat of Solution 
The method used was the procedure described by Higuchi 
et al ( 10 ). Ibuprofen was added in large excess t o buffered 
solut i on s in screw-capped vials at various pHs. The tubes 
were r otated on a labquake shaker in dry ovens for 24 hours 
to reach saturation ( 11 ) . The vials were then centrifuged at 
2000g for 10 minutes, supernatants withdrawn. filtered. and 
further analyzed for pH and drug concentrations. Four pH ' s 
were studied at temperatures ranging from 25 to 51 ° c . 
Solid State Properties 
Particle size was measured using a laser light scatter-
ing technique ( Brinckman Particle Size Analy zer ) . Surface 
areas were determined with a Nitrogen ads orption technique 
and calculated using the B . E . T . equation. This experiment 
was performed on a Quantasorb instrument. Compressibility 
and density were evaluated using a procedure proposed by 
Rees et al (12). About 100 mg of powder were weighted in a 
v o lumetric cylinder . Up to 2000 taps were performed on an 
Erweka instrument. Moisture contents were estimated with a 
Karl-Fisher technique. Crystal analysis included differen-
ti al scanning calorimetry to monitor temperatures and 
enthalpies of fusion on a Perkin-Elmer P7500 , all thermal 
analysis were conducted with a heat fl ow of 5°C / minute; 
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samples were also analyzed through scanning electron micros -
c opy and X- Ray powder diffraction at the R&D analytical 
services o f Ciba-Geigy in Ardsley , NY. 
RESULTS AND DI SCUSSIONS 
Solid State Properties 
Under similar storage conditions ( 22°c +/ - 2 and 35% RH ) 
the mass fraction of moisture for the rac - ibuprofen averaged 
0 . 065 + 1 - 0 . 013% where ( + ) -S-ibuprofen exhibited 0 . 34 + ' -
0.24% of water corresponding to ten times more moisture for 
this enantiomer. After careful analysis of X-Ray diffraction 
patterns of dried and humidity exposed ibuprofen samples. 
there was no change in the crystallinity of both powders 
upon removal of water. It was speculated that the moisture 
essentially sticks to the crystal surface . Both compounds 
had a very low water content but according to Ahelc et al 
( 13 ) they still require special attention because the water 
distributes only in amorphous regions. X- ray powder diffrac -
tion patterns indicated different crystal structure for the 
racemate and its enantiomer with very different deflection 
peaks especially at low angles of the spectrum. Ten minutes 
grinding resulted in a loss of crystallinity for both pow-
ders with a decrease in deflection peaks intensity (fig. 2). 
For ground S(+ ) ibuprofen , some peaks were more intense at 
low angles of the spectrum ( 11-15). This difference might be 
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due to the decrease in particle size but ind i cate d a 
modi f i c ati on of the c rystal nature. The thermodynami c 
pa rameters. presented in table confirmed these conc l u -
sions . The endotherm temperature was 20 ° c l ower f o r the S(-) 
enantiomer and the enthalpy of fusion averaged 35 J t g less 
than the racemate. Upon grinding there was a decrease in the 
enthalpy of fusion for the ibuprofens proportional t o 
entropy changes. There was no modifications in the melting 
points in either case confirming no rearrangement of the in-
ternal lattice ( s ) . Nevertheless . although the internal 
structure might not have been modified , upon grinding there 
was a decrease in the particle size of ( + ) -S-ibuprofen and 
the compound became difficult to handle as a result of 
flowabili t y loss . 
Based on the monolayer gas adsorption theory we calcu-
lated the true surface area of the two compounds using the 
B.E.T. equation . The B . E . T. values for racemate and the S( T) 
isomer were respectively 3 . 4 10-l ( 0.01 ) and 2.8 10- 3 ( 1.9 
10-4 ) m2 1gram indicating a specific surface area more than 
100 times smaller for the enantiomer. Although it has been 
found that BET values vary between sources ( 14 ). the 
amplitude of this difference might be a potential problem of 
the formulation specifically in the 
dissolution / bioavailability behavior. The particle size with 
a mean ranging from 83 to 149 um was very large compared to 
5 - 38 um for the racemate ( 14 ) and was responsible for the 
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excellent flowability of the bulk material. The scanning 
electron microscopy observations in fig.3 indeed confirmed 
the descriptive analysis and the unusual nature of the c r ys-
tal surface o f (+)-S-ibuprofen . The optical isomer existed 
as large box y needle s consisting of the crystal un i t . All 
particles had a very smooth surface. 
Bulk and tapped densities averaged 34 and 56 % respec -
tively and were similar t o the racemate analyzed. The 
compressibility / flowability as evaluated by plotting Log 
Vo / V against the number of t aps ( fig .4 ) . where Vo is the 
initial volume and v the tapped volume. was consistently . 
above the 0 . 1 assymptote for the racemate and considered 
poor ( 12 ) as compared to the S(T ) enantiomer. Thus the opti -
cal isomer might be a good candidate for direct compression . 
Dissolution Kinetics 
Because of the unique dissolution characterisitics of 
each compound. the rate plots presented in fig.5 had dif -
ferent slopes , and consequently different intrinsic 
dissolution rates. Surprinsingly the IPR for S(+) ibuprofen 
averaging 8. -1 -2 ug.sec .cm was smaller than the IPR of the 
racemate with a mean at 11.6 ug.sec - 1 .cm- 2 . It appears that 
under our experimental conditions , the dissolution rate of 
the enantiomer was limited by its very small surface area 
( rather than enhanced by its high solubility) . In addition. 
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age d c ompac t s at Room Temperature f or 3 days a nd further 
analyzed und er the same conditi ons had lowe r int rinsic dis -
solution rat e s I DR than ori ginal disks immedi ately analyzed 
a ft e r manufa cture ( f ig. 6 ). 
Heat of Solution 
The s olubility of the two ibuprofens was determined at 
different temperat ures in vari ous buffers . The van ' t Hoff 
equat i on relates the s olubility in mole fraction or mole 
percent to the inverse of the absolute temperature of an . 
ideal solution: 
-Log Xi ( ~Hf / RT ) + constant 
where Xi is the ibuprofen c oncentration i n mole frac -
tion , ~Hf the heat of s ol uti on , R the perfect gas constant 
and T the absolute temperature in degree Ke l vin . The Van ' t 
Hoff 
plots for rac - ibuprofen ( fig.7 ) and (+)- S- ibuprofen (fig . 8 ) 
y ield heats of solution at different pH ' s presented in table 
2. The slopes varied with pH indicating that the heat ab-
sorbed by the systems during dissolution varied with the 
extent of ionization . The energy of solubilization decreased 
with ionized species and at pH 7.7 , the heat of s o lution be -
came slightly exothermic for both ibuprofens . This result 
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confirmed that when i onization was the principal f a c t or in 
di ssolut i on ( at high pHs ) this phenomena actually release d 
energy . At ohis level of l ower [H+) c oncentrat i on s . S( - ) 
ibupro fen cons istently exhibited l ower heat of s olu t i ons 
than its racemate form showing that the enantiomer i s more 
soluble in aqueous media . For example the aqueous solubility 
of ( - )- S- ibuprofen in a pH 7 . 7 phosphate buffer at 37 °c was 
6.0 mg / ml compared to 5.0 mg t ml f or the racemate . Under our 
experimental settings . at pH 4.5 ( pKa of ibuprofen ) the con -
centrations were most variable and yield close to zero 
slopes for both ibuprofens. 
CONCLUSI ONS 
The physical pharmacy profiles of S(+) ibuprofen and its 
racemate form were compared . Thermal analysis indicated that 
the optical isomer existed as a different crystal form ex -
hibiting different solid state properties which could be of 
concern for the formulator. Particle size was increased and 
the flowability was improved. The enantiomer existed as 
large boxy crystals with unusually low surface area. This 
might be a major limitation for an oral solid formulation. 
In fact the intrinsic dissolution rate of this compound was 
found smaller than the IDR of the rac-ibuprofen which was 
not predicted from the solubulity data and not previously 
documented in the literature. Solubility determinations 
112 
revealed that ( • )-S-ibuprofen was more soluble in aqueous 
media at pHs higher than 4.5 but not to the extent an -
ticipated f r om a review of the stereochemical literature. 
Al so at pH 7.7 heats of solution were slightly exothermic 
for both ibuprofens indicating that at this pH the 
solubilization pr ocess released some energy. It has been 
argued from a pharmacokinetic / pharmacodynamic stand point 
that formulating S(+) ibuprofen might be a therapeutic im-
provement ( 9 ). however, considering these elements of 
physical pharmacy special attention should be given to the 
formulation , in order to overcome the potential problems of . 
dissolution . low melting levels and compatibility . Thus. 
S (+) ibuprofen might be readily absorbed through the j ejunum 
but its dissolution characteristics could be a rate limiting 
step of bioavailability for an oral solid dosage form. If 
lower doses are required , it is anticipated that S(+) 
ibuprofen could be a good candidate for direct compression . 
In summary, we believe that the formulation of (+)-S-
ibuprofen is cert ainly achievable provided the unique 
characterist i cs of t his drug are kept in mind. There are 
significant diffe rences between this enantiomer and t he 
racemate and the potential advantages (therapeutic and 
biopharmaceutical ) of the S(+) drug might be considerable. 
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Table I : THERMAL ANALYSIS OF IBUPROFEN 
"As Received" Racemate S( +) R(-) 
MELTING 0 0 
RANGE 75 - 77 oC 53 - 55 c 53-55 c 
ENTHALPY 
OF FUSION 13 5 .1 J/G 8 6. 8 J/G 87.0 J/G 
"Ground" 
..... 
(j) 
MELTING 
POINT 7 5 . 3 c 55. 1 c 
ENTHALPY 
OF FUSION 11 5 . 2 J/G 8 2 . 3 J /G 
TABLE II: HEAT OF SOLUTION FOR 
(+)-S AND RAC-IBUPROFEN 
pH ~H _, _, 
(KJ.lolOLE • • K) 
RAC-IBUPROFEN 1.3 32.2 
4.5 -0.3 
6.0 38.8 
.... 7.7 -5.2 
.... 
-;z 
( + )-S-IBUPROFEN 1.3 51.5 
4.5 -0.04 
6.0 29.9 
7.7 -16.4 
Figure l 
cross-section ot the Modified Woods Rotating Apparatus 
JJ 
disk holder 
i-------i--die hole 
ie 
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Figure 2 f Grinding "as 
Effect 0 ofen 
. Patterns: . S (+) ibupr ei v ed" Diffraction d " ( B ) "as re c Powder X-R~:, profen " g rco.217 b.; p r of en (A ) : S(+) l" ( C ) : R a 
r eceiv ed , 
(A) 
(8 ) 
U I ' \ 11 I VI 1 1,11~~ (CJ 
119 
Figure 3 
Scanning Electron Microscopy Photographs of S(+) Ibuprofen 
so , 250, soo and lOOOX Magnification 
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( MANUSCRIPT V 
STEREOCHEMICAL ASPECTS OF THE MOLECULAR PHARMACEUTICS 
OF IBUPROFEN 
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ABSTRACT 
Thermal analysis. thermody namics of s olution and 
molecular modeling of (+)- S- ibuprofen and rac - ibuprofen gave 
information on how heterochiral or homochiral interactions 
would affect the processing of ibuprofen. The study con -
firmed that rac-ibuprofen exists as a true racemate with a 
10% eutectic pure enantiomer composition. Both the racemate 
and the ( +) isomer crystal unit cells include four molecules 
and crystallize in the P2 1 / c and P2 1 space groups respec -
tively. Thus the intermolecular forces were different _ 
between the crystals. As a consequence the (+) enantiomer 
lattice was more fragile but only slightly more soluble than 
the racemate in aqueous media. The solid- state structure 
contributions to solubility were very different between the 
two crystals (AH~( +)- 51 . l and AH~ac- 32.2 in KJ mole ) but 
the standard free energy of solution were found to be com-
parable for both compounds. 
INTRODUCTION 
It is generally recognized that (+)-S-ibuprofen is the 
enantiomer of ibuprofen inhibiting the prostaglandin syn-
thetase (1 - 2 ) . Stereospecif ic and conformational 
characteristics of this isomer are required for interaction 
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with the cell receptors responsible for the therapeutic an-
tiinflammatory activity. Another consequence of chirality 
could be the differences between the crystal habit of the 
tw o s e parate isomers and the racemate. We now report a con-
tinuation of our studies in this area ( 3). 
We have previously reported higher solubility , lower 
melting point and smaller intrinsic diss olution rate s f or 
the (+) isomer compared to the racemate form ( 3 ). The com-
bination of tests used in this study is , we believe , 
essential when one is investigating a chiral compound or an 
optically pure isomer. For example , the thermal behavior of _ 
sobrerol and diastereoisomers was reported ( 4 ) and the crys-
tal structures of cytostatic agents (stereoisomers and 
mixtures ) were elucidated (5), both in support of formula -
tion efforts. In another study the thermodynamic functions 
of solution of non steroidal antiinflammat or y agents , in-
cluding ibuprofen have been thoroughly studied by Pecci e_t_ 
al (6) to determine the contribution of the solid state 
structures in promoting solubility. The physical charac-
teristics can be related to the molecular packing of the 
crystals under study ( 7 ) . 
The combination of all these tests and the comparative 
analysis is a unique approach to the formulation of 
ibuprofen enantiomers that has been largely overlooked 
before the stereospecific synthesis became economically vi -
able . 
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EXPERIMENTAL 
Materials 
Racemic and S(+) ibuprofen were supplied b y the Ethyl 
Corp. ( Baton Rouge . LA ). Methanol from the Fisher Scientific 
Co. was used for ibuprofen recrystallization and was of 
analytical grade. Potassium phosphate monobasic and sodium 
hydroxide were obtained from the Malinckrodt and J . T. Baker 
chemical companies , respectively. 
Me thods 
Thermal Analysis: Ibuprofen mixtures containing various 
enantiomeric proportions were prepared by slow recrystal -
lization at 42 .6 °F from methanol and after melting. Thermal 
analysis were performed on (-)- S- ibuprofen [S (+)J. (-)-R-
ibuprofen [R(-)] , rac-ibuprofen [Rael and mixtures using a 
differential scanning calorimeter [DSC] from Perkin Elmer, 
series 7. The heating rate was set at 5 °c1minute under 
nitrogen flushing . Thermal endotherms were integrated t o ob-
tain thermodynamic functions used for the phase-diagrams. 
Theoretical solid-liquid equilibr ium curves were drawn using 
the Prigofine- Defay equation ( eq.l ) for the racemate com-
pletely dissolved in the melt and the Schroeder Van - Laar 
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( equati on ( eq.2 ) for che simple eutectic formation (9). Thus. 
eutect i c temperature and compositions could be determined: 
Ln4x ( l - x ) equation 1 
Lnx equati on 2 
where x is the mole fraction of the more abundant enan -
tiomer in the mixture. whose melting ends at Tf (°K) AHs 
and AHrac are the enthalpy of fusion of the pure S(+) and 
the r acemic form respectively: Tms and Tmrac are the cor-
responding melting points and R is the gas constant at 1.987 
cal.mol- 1 . _ °K- 1 . 
Crystal Analysis: Single crystal X-ray diffraction was 
performed on small crystals o f (+)-S- ibuprofen from the 
bulk compound. Reflection data was obtained from Ethyl Co . 
and processed on a molecular modeling program (Shelxtlr ). 
Crystal data is given in Table I . The structure was solved 
in the space group P2 1 / c Analysis of the unit cell allowed 
the identification of the molecular packing and hydrogen 
bonds network within the monoclinic crystal . Similar infor-
mation on the racemate was obtained from the literature ( 10) 
and compared to the newly obtained molecular packing data of 
the (+) enantiomer . 
Solubility: Excess amounts of both compounds were 
suspended in 0.05M aqueous buffered solutions at pH 1.3. At 
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this pH. the drug is essentially unionized since the 
ibuprofen pKa is believed to be in the range of 4.6 to 5 .2 . 
Screw cap vials were rotated on a Labshaker for 24 hours at 
temperatures ranging from 25 ° to 52 °c in walk-in ovens. 
Quantitative analysis was performed using ultra violet 
spectrophotometry at selected wavelengths (220 and 264 nm ) . 
The thermodynamic functions of solubilities were evaluated 
as follows: 
The chemical potential of a solute (s) in equilibrium 
with its pure form (s) may be written as: 
µ µ + R'T *Ln x equation 3 
The variation of the solubility expressed in xw (mo le frac -
tion in the solution ) can be integrated to 
Cstant + ( - ~Ho I R) > ( l / T ) equation 4 
and experimental data can be analyzed by plotting Ln of the 
solubility versus l / T. The free energy of solubility at a 
given temperature can be obtained from 
-R *T*Ln xw equation 5 
and the entropy of solution is derived from the third law of 
thermodynamics: 
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e quat i on 6 
Al l thermody namic parameters were analyzed t o compare 
the racemate and S (+) ibuprofens. The c ontribution of 
ibuprofen stereochemistry ( solid state structures ) t o 
solubility , was investigated In a recent study, ther -
modynamic functions were used to predict and separate the 
roles of solid- state struc tures from s olute - s olvent interac-
tions in promoting the solubility of a solid nonelectrolyte 
( 6 ) . 
RESULTS AND DISCUSSION 
Thermal Behavior 
Thermodynamic functions f or both compounds are reported 
in Table II. Melting parameters ( Tm and 6H ) obtained from 
the thermograms in figures 1 - 2 , were used in equations l and 
2 to obtain the phase - diagram in figure 3 (10 ) . Experimental 
data were in good agreement with the theoretical lines in-
dicating the fusion of the Eutectic at about Teu_ 321 °K and 
a eutectic composition of 10.0 % on each side. As previously 
anticipated ( 3 , 10 ) the thermal analysis confirmed that 
ibuprofen naturally occurs as a unique racemic compound. A 
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Peter son "i" ratio of 1.77 was calculated from equati on 7 
( 9 ) : 
" i " equation 7 
where Tmeu is the eutectic temperature as determined ex -
perimentally and from the phase diagram. 
Although somewhat arbitrary in character. this rati o 
clearly indicated that ibuprofen has a strong tendency t o 
crystallize as a true racemate. The melting point of both 
optical isomers was 20 to 22 °c lower than the racemate f orm -
and eutectics were very close to the edges of the diagram 
making any enantioselective resolution by crystallizat ion 
impossible . The test of the Prigofine- Defay equation was 
perf ormed a posteriori and the straight line in figure 4 
confirmed the model. 
Crys tal Packing 
Perspective drawings of the molecular packing in the 
crystals of (+)-S-ibuprofen are given in figures 5a-5c. 
(+)-S-ibuprofen is more water soluble than the racemate ( 3 ) 
and it is of interest to seek the basis for the differing 
solubilitie s or thermal behavior in terms of intermolecular 
attractions forces. Although having the same number of 
molecules , S(+) crystals have a totally different unit cell 
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than the racemace ( Fig.5a ). The array of S molecule s in-
volved in homochiral interactions probably spreads the 
mechanical stability / strength of the crystal ( Fig.5b ) . The 
preferential molecular arrangement in the P2 1 plan exhibit 
some of the acid groups " face-up " and others "face down· so 
that all the layers of molecules are interconnected with 
pairs of hydrogen bonds to carboxyl groups. As suming that 
the top layer of the c r ystal is one. crystal surface is dif -
ferent for the two compounds. Thus in the case of C~)- S -
ibuprofen there are more exposed carboxyls and less 
hydrophobic layer s. There are several points of interest: _ 
first the greater number of crystallographically independant 
molecules in the S crystals ; secondly there are no obvious 
relationships between molecular packing in the lattice of 
racemate and enantiomers . Finally. the structural data 
reflects different intermolecular environments. In order to 
pack together, molecules of the same chirality had to be 
somewhat flexed in order to meet the space requirements of 
the lattice. A qualitative measure was the superposition of 
two (+)-S- ibuprofen molecules involved in the same hydrogen 
bond which clearly demonstrate the torsion (Fig.5c). We 
hypothesize that further crystal elasticity or fragility 
would result from the packing. 
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Solubility 
The s o lubility of crystalline solid is determined b y che 
free energy changes from the solid state to a solution . As 
indicated in table II. ~Go at 25 °c is slightly higher f or 
the racemate than for its S C~) isomer which may account for 
the differing solubilities. Similar conclusions could be 
drawn from the analysis of fusion parameters. The enthalpy 
and entropy contributions to water solubility as revealed by 
the thermodynamic functions in table II. are very different 
suggesting that solid state structures are responsible for 
these differences. 
CONCLUSI ONS 
It was confirmed that rac-ibuprofen naturally occurs as 
a racemic compound (10) with a eutectic temperature ap -
proaching 320 °K. This behavior although quite conventional . 
has some serious implications in the formulation of the 
biologically active stereoisomer. Heterochiral interactions 
formed preferentially. Thus, both qualitatively and quan -
titatively, the intermolecular network of interactions in 
crystal unit cells of the racemate significantly exceeds 
that existing within cells of the pure enantiomer and can 
also reasonably account for the differing solubilities. 
thermal behavior and further processing characteristics. The 
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literature ind i cates chat in some ins tances. when the melt -
ing po inc of pure stereoisomers is substantially l ower. 
these optical isomers are several fold mo re s oluble than the 
corresponding racemate ( 5,8 ) . In this case, the S isomer was 
only slightly more water soluble than r ac -ibuprofen . We at -
tribute this phenomena to the molecular arrangement in the 
lattice of ( +)-S- ibuprofen . Solid- state structure contribu-
tions ( ~H ) to s olubility were different between the (+) 
isomer and the racemate. At pH 1 .3 the entropy effect ( ~S ) 
counterbalanced this effect and standard free energy were 
almost equivalent for the two c rystals. These results con-
firmed the l ow specific surface area and the slow intrinsic 
dissolution rate of ( +)- S- ibuprofen. In addition , the crys-
tal lattice exhibi ted potentials for mechanical instability 
if perturbed by components of high hydr ogen bonding af -
finities. 
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Table I: Crystal Data for (+)-S-Ibuprofen and Rae-ibuprofen 
(+)-S-ibuprofen Rae-ibuprofen 
Formula Cl3H1802 C13H1802 
Molecul.Weight 206.3 grams 206.3 grams 
Crystal System Monoclinic Monoclinic 
Space Group P21/c P21 
a( i\) 12.46 14.67 
b(i\) 8.03 7.88 
,_, c( i\l 13.53 10.73 
"" 
()l(i\) 
0 ( ) 112. 95 99.36 ~( e 
# of molecules 
in the cell 4 4 
Density (g. cm ) 1. 098 
CuK GI Radiation 
Table II: Thermodynamic Functions of Melting and Solubility 
Ibuprofen Rae (+)-S (-)-R 
-
Melting 
Tm Melting Point (~K) 
·1 
349 327 327 
oH Enthalpy (KJ.mole ) 25.5 17.9 17.9 
· 1 · 1 
>--' oS Entropy (J.mole ·~ K ) 73.2 54.8 54.8 ti> 
>--' 
Solution 
· 1 
oH ( KJ.mole ) 32.2 51. 5 
· 1 
oS ( J.mole .o K ) 6.7 73.4 
· 1 
oG, < KJ.mole ) 30.2 29.6 
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MANUSCRIPT VI 
FORMULATION OF THE BIOLOGICALLY ACTIVE 
STEREOISOMER OF IBUPROFEN 
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ABSTRACT 
As part of an effort to formulate the biologically ac-
tive stereoisomer of ibuprofen. the effect s of 
pharmaceutical processing on rac-ibuprofen and ( +)- S-
ibuprofen crystals were compared. This comparative analys i s 
is a unique concept used in stereoselective formulati on. It 
was not found possible - - formulate the (+ ) isomer using 
wet granulation , however direct compression appeared most 
promising. Tablets so formulated showed rapid diss olution 
and other tablet properties were fully acceptable. Mixing . 
with excipients decreased the enthalpy of fusion of 
ibuprofen and compaction induced low temperature eutectics 
indicated by DSC endotherms. Stress storage of the (+)-S-
ibuprofen seriously affected the handling properties of the 
dry formulations. 
INTRODUCTION 
With the exception of Naproxen, all profens currently 
used as non-steroidal antiinflammatory agents are marketed 
as racemates ( 1). For most of these drug substances the 
dextro-rotary or S(+) optical isomer seems to be responsible 
for the therapeutic activity , that is the stereospecific in-
hibition of cyclooxygenase. In addition , various 
pharmacokinetic reports have been published suggesting that 
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for some of these aryl p r opioni c acids. bioinve rsion of the 
inactive enanti ome r int o the active isomer S(-) take place 
in vivo. by enzymatic mechanisms ( 2 ) . For ibuprofen. a s much 
as 33% of the S(+) fo rm could result fr om this biotransfor-
mation. Thus a racemate (containing 50% of R( -)) could yield 
2 / 3 of active ibuprofen in the systemic ci rculation ( 3 ). 
Unfortunately, this pharmacokinetic rationale is only 
one of the factors which must be considered for the success -
ful f ormulation of the pure enantiomer in a drug delivery 
system . Previous investigations by Romero et al ( 4 ) have 
shown that the presently available (+)-S-ibuprofen has a 
relatively small specific surface area which might be some-
what of an impediment to bioavailability (although 
solubility was found higher than the racemate). Some han-
dling properties such as flowability were greatly improved 
while compatibility screening indicated substantial crystal 
distortion under processing ( low temperature eutectic ). The 
molecular packing structure in the crystal lattice was 
elucidated ( 5 ) and it was concluded that (+)-S- ibuprofen ex-
ists as a totally different crystal than the racemate form. 
Analysis of homochiral interactions also revealed that the 
enantiomer crystal might be fragile and more susceptible to 
distortion. 
The study of a pure enantiomer as an answer for a phar -
maceutical problem is not new in process development ( 6 ) but 
the analysis comparing the relationships between molecular 
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aspects of crystal stereochemistry and biopharmaceutical 
performances appears to be a new approach co stereospecif ic 
drug formulacion. Recommendations on the processing of ( + ) -
S-ibuprofen were f ormulated based on this study and previous 
reports. 
EXPERI MENTAL 
Materials 
Ibuprofens (racemate and S isomer) were obtained from _ 
the Ethyl Corporation ( Baton Rouge. LA ). Fast flow lactose 
(Sheffield). polyvinylpirrolidone ( GAF) and Explotab ( Edward 
Mendell) were selected as diluent. binder and disintegrant 
respectively . Simulated intestinal fluid was prepared using 
potassium phosphate monobasic ( Fisher Scientific ), distilled 
water and the pH adjusted to 7.4 with sodium hydroxide 
(Malinkrodt) . 
Methods 
A formulation program was undertaken, including a com-
patibility screening, tablet manufacture a nd analysis of 
biopharmaceutical properties. 
As in previous investigation (7), emphasis was given to 
the study of crystal modifications during processing and 
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their effects on the performance of the final product for 
both ibuprofens . 
Thermal a nd Compa t i b i lity Studies 
Calorimetry was the analytical tool selected for these 
studies. A Perkin Elmer Series 7 thermal unit was used. A 
P7500E computer. interfaced with the system. all owing data 
aquisition and integration of the thermal endotherms . 
Systems o f increasing concentrations of (+)-S- ibuprofen and 
excipients were mixed at room temperature for 24 hours on a 
Labshaker rotating at 40 RPM. Table I summarizes the ex-
perimental design . Samples were withdrawn , tested for 
differential scanning calorimetry ( DSC ) profiles on a Perkin 
Elmer differential scanning calorimeter and stability after 
exposure to the followi ng stress conditions in humidity 
chambers ; 37 °c at 85 % relative humidity ( RH) , and 50°c at 
75% RH for one and seven days. Macroscopic observations were 
also recorded. Tablets made of 67% (T)-S- ibuprofen and ex -
cipients were ground and analyzed for endotherms to assess 
crystal mod if i cation. 
Attempts made to formulate the (+)- S-isomer into tablets 
by wet granulation wer e unsuccessful . It was found impos -
sible to dry the granule s at temperature s between 30 a nd 
40°c. A direct compression formulation was deve l oped using 
the same excipients used for the racemate and compared to 
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tablets havi ng t he same rac - i buprofen concentration. Tablets 
of rac-ibupr ofen were prepared according to a formulation 
design already validated ( 6). Dry mixtures of 67% (-)-S-
ibuprofen. 23% Fast flow lact ose . 6% binder and 3% 
disintegrant ( Explotab ) were prepared using a V- blender 
r otat ing at 30 RPM for ten minutes and further lubricated 
with 1% magnesium stearate for five minutes. A Carver 
hydraulic press was used to produce 350 mg tablets at 2500 
lbs compression force for a 15 second dwell t ime. Three 
regions of the compaction spectrum (low. intermediate and 
high ) were also investigated f or crystal distortion . The ex -
perimental protocol included measurement of disintegration 
time , hardness . dissolution profiles and thermal analysis. 
When possible statistical analys is was performed at the 
95% confidence level either using a paired t test or ANOVA 
to compare (+)-S-ibuprofen and Rae-ibupr ofen powders. 
RESULTS AND DISCUSSION 
DSC profiles of ibuprofen mixtures were integrated for 
melting points , enthalpy of f usion and heat capacity. Mixing 
with excipients had an influence on the thermodynamic 
parameters of fusion largely due to increasing amounts of 
impurities (table II ) and the extent of surface crystal dis -
tortion appeared inversely proportional to the ibuprofen 
concentration. Similar observations were made f or the 
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racemate. The mixtures became more difficult to handle with 
increasing concentrations of (+)- S- ibuprofen. Samples of the 
formulations. kept at different temperatures and relative 
humidities ranging from 35° t o 50°c and 35 to 85% re s pec-
tively were withdrawn at dif ferent time intervals . After 
only 24 hours under the above storage conditions it was im-
possible to handle any mixtures which had been stored at 
50°C , 37°C and 75% RH . All high strength miniformul ations 
had "melted ". After one week of storage at r oom temperature 
the thermal analysis revealed that eutectic f ormation lower -
ing the melting point and heat of fusion (table III ) _ 
apparently made the ibuprofen mechanically unstable. 
It appeared that S(+) had a greater tendency t o form eutec-
tics than the racemate with the selected pharmaceutical 
excipients. The crystal distortion is further facilitated by 
stressful mixing ( e.g. planetary mixer ). This observation i s 
in agreement with the previous analysis of molecular ar -
rangements in the crystal unit and the peripherical 
localization of the intermolecular "Hydrogen" bond network 
of the (+) enantiomer (7). 
Biopharmaceutical analysis was performed on the 350 mg 
tablets. Conventional rac-ibuprofen formulations ( using Wet 
Granulation ) were compared to (+)-S-ibuprofen (Directly 
Compressible ) formulation. Disintegration times averaged 
8 '( 4 ') for the S(+). These tablets did not erode as did the 
corresponding racemate tablets averaging 53 '( 6 ') . instead 
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they disintegrated rather quickly and became a paste stick -
ing to the grid. The mean hardness for these tablets was 
30 (1 9 ) N. 
Using a procedure testing for the extent of crystal 
modifications in solid dosage forms ( 7 ) thermodynamic 
parameters of ground tablets were analyzed to compare (+)-8-
ibuprofen to the racemate. Results of the calorimetric 
analysis are presented in table IV and figure l. Thermal en -
d otherms of mixtures after compaction indicated a "clear " 
eutectic ( first endotherm) at lower temperature. The eutec-
tic also appeared after three days of mixing and was not . 
proportional to the compaction level, as was previously 
found fo~ the racemate (7). As predicted from molecular 
modeling the manifestation 
compaction are different 
racemate. 
of lattice rearrangement upon 
between (+)-8-ibuprofen and the 
Although higher intrinsic dissolution rates had been 
found for the racemate (partly due 
size), the dissolution for 67% 
to its small particle 
(+)-8-ibuprofen from the 
directly compressible formulation was faster than for the 
racemate (Table V). The time for 50% dissolution of (+)-8-
ibuprofen was three times smaller (figure 2 ) and at twenty 
minutes 58.2(12)% ( average ( 8D )) of (+)-8 isomer had dis -
solved whereas only 22.8(4) % of rac-ibuprofen was released. 
It is speculated that the presence of excipients and crystal 
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distortion might be bene ficial in enhancing the dissolution 
of the S isomer. 
CONCLUSIONS 
The results of this 
preformulati on profile ( 6 ) 
study were in a greement with a 
reporting that (~ J -S-ibuprofen 
crystal particles are very "fragile" and loose their han-
dling properties when stressed or ground. Therefore further 
processing will require a gentle mixing. Crystal arrays of 
(+) and (-) molecules in racemic crystals are totally dif -
ferent than molecules in the lattice of (T)-S- ibuprofen ( 7 ). 
As a consequence. crystal distortion was significantly dif -
ferent between the two compounds. In additi on to 
modification of the crystal habit. the S isomer exhibited a 
eutectic upon compact ion . The dissolution of (+)-S-ibuprofen 
from the dosage forms was faster when compared to the 
racemate . It is hypothesized that the particle size 
decreased upon compression and / or the excipients improved 
the dissolution . Another result of the thermal analysis in -
dicated that as observed for the racemate. excipients 
protected the ibuprofen crystal from further distortion. 
Lower strength formulations had decreased heat of fusion but 
improved mechanical properties . 
In conclusion a directly compressible formulation of the 
S(T) isomer is a feasible alternative to the conventional 
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wet granulation formulation currenoly used for rac -
ibuprofen. Based on the analysis of the stereoisomer at the 
molecular level , suggestions for future work can be formu -
lated. Research for neutral excipients including flow 
properties and the effect of storage under various condi -
tions could bring practical answers. Mixing (time and 
techniques ) appear to be critical . It is important to 
preserve the S crystal intact before tabletting. Finally. 
the effect of storage on the biopharmaceutical properties of 
the tablets should be studied. There was eutectic formation 
resulting from compaction. 
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Table I: Experimental Design 
a a 
Formulation A B 
(+)-S-ibuprofen 17 37 
Binder (PVP) 6 6 
Diluent (F.F.Lactose) 73 53 
Disintegrant (Explotab) 3 3 
Lubricant (Mg.St.) - -
*· Tabletted at several compression forces 
(ranging from 600 to 15000 lbs) 
a. subjected to stress storage 
a * a 
,, c D E 
57 67 77 % 
6 6 6 % 
33 23 13 % 
3 3 3 % 
- l - % 
I-' 
m 
(\) 
Table II: Thermal Analysis of (+)-S Formulation (24 hr mixing) 
Formulations: 
Thermodynamic Pure 
Functions ibuprofen A B c E 
0 a a a a a 
Melting Point (Tm in K) 327 325.5 325.8 326.4 326.4 
Enthalpy of Fusion (KJ/mole) 
average +/- (SD) 18.3 11. 6 14.6 16.0 16.5 
(0 . 2) ( 1.1) (1.6) (1.1) (1. 0) 
a. Relative standard deviation (RSD) less or equal than 0 . 05 
,..., 
Ol 
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Table III: Thermal Analysis of (+)-S Formulation (One week storage at RT) 
Formulations: 
Thermodynamic Pure 
Functions ibuprofen A B c E 
0 a 
Melting Point (Tm in K) 327 324.2 325.0 325.3 325.5 
Enthalpy of Fusion (KJ/mole) 18.3 +/- 10.5 12.7 16.2 15.4 
0.2 
a. Relative standard deviation (RSD) less or equal than 0 . 05 
,_, 
Ol 
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Table IV: Thermal Analysis of (+)-S-ibuprofen Tablets (67%) 
Effect of Compaction 
1 1 2 2 
Compression Force Tm .6H Tm AH 
0 0 
(KN) ( K ) (KJ/mole) . ( K ) (KJ/mole) 
a 
0.0 - - 327.8 18.3 
b 
o.o - - 325.7 17.3 
c 
o.o 314.5 1. 79 325.4 16.8 
2.7 313. 9 0.66 325.1 16.9 
5.3 318.1 0.92 324.7 16.2 
10.7 314.3 0.53 325.7 17.7 
22.2 314 .1 0.53 325.9 18. 6 
26.7 313. 8 0.68 325.4 17. 5 
35.6 314 . 5 0.35 326.2 19.0 
44.5 314 .0 0.41 325.7 18.5 
a. Pure (+)-S-ibuprofen "as is" 
b. 67% (+)-S-ibuprofen formulation after ten minutes of mixing 
c. 67% (+)-S-ibuprofen formulation after three days of mixing 
'-' 
Ol 
(JI 
Table V: Biopharmaceutical Properties of Ibuprofen Tablets 
Ave rage +/- (SD) 
Time for 50% % Dissolved Hardness Disintegration 
(Minutes) in 20 Min . (KN) Time (Minutes) 
(+)-S-ibuprofen 17 58.2(12) 30.0(19) 8 ( 4) 
.. 
Ra e-ibuprofen 5 3 22.8 (4) 22. 2 (5) 53 ( 6 ) 
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CONCLUSIONS AND SUGGESTIONS FOR FUTURE WORK 
In the early stages of this study. I defined tests and 
methods that made possible the identification of crystal 
properties that affect the processing of ibuprofen. It was 
shown that different sources of ibuprofen , all meeting the 
United States Pharmacopeia compendial standards , had very 
variable crystal characteristics. These differences had a 
dramatic effect upon the selection of processing parameters 
and not all the sources of ibuprofen can be regarded as in -
terchangeable . This report is one of the first promoting the -
use of different standard operating procedures (SOP's) for 
sources from different suppliers of ibuprofen. Also . given 
the five sources of this NSAID agent , it is conceivable that 
it might be advantagous to make USP standards more rigorous. 
I have no reason to doubt that other drugs may also require 
this adjustment of the formulation process if they are ob-
tained from different manufacturers or different synthetic 
routes. 
This study underlines the importance of crystal en-
gineering and strict physical pharmacy profiles in drug 
development. I was able to demonstrate , with relative con-
fidence that sintering is the molecular mechanism by which 
ibuprofen transformation is achieved during formulation. A 
resulting hydrophobic network within tablets was the cause 
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of many formulation problems with chis compound. Several 
analytical tools usually re served to other fields of phar -
maceutical research ( e.g. SEM. DSC. molecular modeling ) 
proved extremely useful and should be incorporated in 
regular formulation / preformulation activities especially 
when single isomers are being considered as replacement for 
racemic drugs. 
The same methodologies were applied to the analysis of 
the (-)-S- ibuprofen . It is well established that drug sub-
stances with a chiral center may exhibit pharmacologically-
active and inactive stereoisomers. When this is the case. 
there might be indeed a powerful argument to replace 
racemate with the single pure enantiomer. The rational for 
this change has to be carefully reviewed. 
It is believed that this thesis is one of the first 
report to demonstrate that in addition to biological dif-
ferences (previously publicized ). rac- ibuprofen and (+)- S-
ibuprofen are essentially different in terms of processing 
and formulation. Both quantitatively and qualitatively dif-
ferences in homo and heterochiral interactions can account 
for a certain degree of the differences in mechanical 
properties and solubility . For example, direct compression 
is impossible and wet granulation is the only way to formu -
late the racemate. whereas the reverse may be true for the S 
isomer . Some characteristics of the racemate must be kept 
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in mind but I c an assess with confidenc e that the (-)- S-
i bupr ofen is a totally independent crystal that s hould be 
for mul a ted a s a new drug subs tanc e . 
The comparative analysis o f molecular pharmaceutic s of 
the racemate and stereoisomers revealed a u seful tool f or 
stereospecific drug development. Enantiomers should be con-
sidered as early as possible as new c andidates fo r 
formulation. I t may well be that conclusions for ibupr ofen 
could be applied to others chiral compounds and in view of 
the above factors. I strongly recommend that all changes 
from racemate to pure isomers be subjected to extensive _ 
molecular scrutiny in early preformulation program . using 
the approach that was designed. 
My results suggest, however. that more studies on the 
effect of stress storage of ( +)- S- ibuprofen and its formula -
tions should be conducted. This compound is very fragile. 
Formulators must proceed with extreme caution as it is more 
likely that ( +) - S-ibuprofen will sublime even at room tem-
perature. Other studies are currently under way to refine 
the model of stereospecific bioinversion in man . adding a 
feed back inhibition from the S isomer. Such studies could 
involve the administration of different enantiomeric com -
position in a rat model and the monitoring of systemic 
plasma concentrations of S and R ibuprofen. A faster absorp-
tion of (+)-8-ibuprofen has been observed when this isomer 
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is administered within the racemate form than alone. 
Optimizing i buprofen therapy could lead to administering a 
small amount of (-) -R-ibuprofen. In this thesis it was found 
that chiral bioinversion occur essentially systemically. The 
results suggested that enantiomeric AUC ratios were ex-
tremely powerful in studying realistic ibuprofen 
pharmacokinetics. 
The work reported in this dissertation has demonstrated 
that careful attention has to be directed to crystal charac-
teristics and physico-chemical properties of raw materials. -
Consequently USP compendial standards should be more 
rigorous. The results clearly indicate that a profound 
change of the approach to formulating drug substances is 
necessary using combinations of new testing methods readily 
available. This concept is in my opinion essential when the 
drug substance includes a chiral center and developing pure 
isomers might be a possibility. 
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MANUSCRIPT VII 
USE AND LIMITATIONS OF THE TRUNCATED 
AREA UNDER THE CURVE IN BIOEQUIVALENCE TESTING 
1 7 4 
ABSTRACT 
Computer simulat i ons were used t o evaluate the truncated 
area under the plasma level - time curves ( AUCt ) as indicators 
o f the bioequivalence between test and reference products. 
Plasma concent rations were simulated from one and two corn-
partrnent open models using first order absorption rate 
constants ( Ka ) and bioavailability ( F ) ranging respectively 
from 45 to 200% and 60 to 140% of the reference values. The 
pharrnacokinetic parameters were selected to cover a wide 
range of disposit ion rate constants (0.0 1-0 .79 hr . - 1 ) . The-
area under the blood level - time curves was calculated using 
the trapezoidal rule at each time point ( t ) according to a 
conventional sampling regimen. The extent of absorpti on 
( AUCinf ) was calculated , using integrals of the general 
blood equations. The ratios of AUCt: test to reference and 
AUCt t o AUCinfwere determined. For most simulations . the 
ratios changed very little between the end of the absorpti on 
period. the last time point and the time infinity . 
AUCtrnax was not a good parameter t o compare the 
bioavailability of two drug products. Three groups of dif -
ferent mathematical behavior were identified , in which 
bioequivalence determination might present some problems 
when using a single AUG. Several truncated AUC ratios, 
however. could provide meaningful information on absorption 
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rates for bioequivalence testing. In our study the Auc8 0 was 
consistently a good indicator of bioequivalence. 
I NTRODUCTION 
Since the seventies. the rate of discovery and develop-
ment o f new therapeutic entities has been decreasing while 
the number of major drugs going off patent has been increas-
ing ( 1 ) . As a result there has been a steady expansion o f 
the generic market (2). This phenomena was enhanced by the 
Drug Price Competition and Patent Restoration Act which ex - -
pedited the approval of generic drugs.Under this act, the 
therapeutic equivalency of generic products may be assessed 
on the basis of a bioequivalence test. The fundamental as -
sumption being that once in the general circulation, the 
same active drug undergoes the same disposition and metabo-
lism independent of the dosage forms . Therefore, drug 
products showing "similar " bioavailability could be termed 
bioequivalent according to specifications provided by the 
Food and Drug Administration ( FDA ). 
Bioavailability has been defined as the rate and extent 
at which a drug ingredient is absorbed from the drug for-
mulation and becomes available to the site of action (3). 
Details on the experimental design and statistical tech -
niques for these bioavailability studies have been described 
extensively elsewhere ( 4 - 5 ) and for some drugs the Division 
176 
of Bioequivalence at the FDA provides guidelines for the 
required in-vivo bioequivalence study ( 6). In our reporc . 
the staciscical issues. although int i mately related to bie -
quivalence inferences , will not be discussed. The rat ios of 
area under blood level profiles for reference and test 
products will be analyzed. 
To date , although no cases of bioinequivalence be tween 
approved drug products have been documented . the re are some 
reports showing concerns on the therapeutic efficiency of 
generic products (7- 11 ). In a recent analysis. however , the 
FDA found that in 80% of 224 bioequivalence studies , the _ 
difference of area under the plasma level -t ime curves for 
the tests to reference products averaged 3.5% ! 5% (1 2 ). 
For such products , the natural intersubj ect variabilit y is 
more likely to affect the pharmacodynamic response of drugs. 
than differences in bioavailability ( extent and rate of 
absorption ). While AUCinf provides complete information on 
the ultimate extent of absorption. Cmax ( maximum peak 
concentration) and Tmax ( time to the peak ) are dependant on 
the sampling regimen . Therefore , the confidence interval for 
those parameters is often wide and the regulatory agency 
gives less weight to the variation of these parameters (12). 
Thus , there is a need for alternative parameters to provide 
more reliable information on the rate of absorpt i on ( 15 ) . 
Two recent reports suggested that more emphasis should be 
placed on truncated area under the blood profiles ( AUCt or 
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AUCxx· where t is the sampling time corresponding to XX per -
cent of the AUCinf ) in the determination of bioequivalence 
( 16.23 ) . Many bioequivalence studies compared AUCtlast 
(tlast =time of last measurable concentration ) (17 - 19), but 
only recently. few used the truncated area AUCt ( 22 ) or ad -
dressed the pharmacokinetic relevance of this parameter 
(20,2 1 , 23). In Japan. statistical testing on AUCtlast 
instead of AUCinf is required to assess bioequivalence be -
tween two products (19). The issue of the last sampling time 
remains a question mark. The approach required by the FDA is 
that AUC's should be calculated from plasma levels which _ 
have fallen to at least 10% of the peak concentration. This 
method is useful but empirical. In essence. there is no 
simple rule of thumb governing the principles of bioe-
qui valence testing. 
The objectives of this computer simulation are to inves -
tigate the use and limitations of truncated areas in 
bioequivalence studies and to stress the pharmacokinetic 
relevance of this parameter. We hope to define rational 
limitations and boundarie s in the practical use of incremen-
tal AUC 's. Our goals are to demonstrate that ratios of 
truncated AUC's can be used with good reliability in bioe-
quivalence testing as they conform to both the statistical 
appropriateness and 
relevance 
the pharmacokinetic / pharmacodynamic 
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METHODS 
Plasma levels were simulated from one and two compart -
ment open model equations using first order elimination 
constants ( KE ) ranging from 0 . 04 to 0.2 hr - 1and sets of al -
pha ( a ). beta(~) fr om 0. 17 t o 0.79 and 0.01 t o 0. 17 
hr - 1respectively . For each KE and each set of a ,~ the phar-
macokinetic parameters characterizing the dosage forms. 
bioavailability ( F ) and rate of absorption ( Ka ), were ranged 
from 60% to 140% and 45% to 200% of the reference product 
values . All conditions are reported in table I and II. All 
necessary nomenclature is given in the appendix. It is well _ 
known that AUCinf remains constant with varying rates of ab-
sorption and we were interested in observing the behavior of 
truncated areas in the various combinations . The one com-
partment open model ( figure 1 , equation 1 ) and the two 
compartment open model ( 24 ) with elimination from the 
central compartment , ( figure 2. equation 2 ) were used in 
these simulations. 
Ct ( F.D.Ka / V) . ( e - KEt _ e - Kat ) eq.l 
Ct Ka.F.D. ( K21 - a ) [ e - atl + -v~cfa=a ;~c~=a ;-
Ka.F.D.(K21- ~) [ e- ~ tl + -v~cfa=~;~ca=~;-
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e q . 2 
The dispositi on parameters for a drug. were assumed t o 
be independent o f the dosage f orm and for each KE or set of 
C a .~) . the pharmacokinetic parameters of the dosage fo rms. F 
and Ka were varied. The reference products that we ar -
bitrarily designated for comparison purposes had the same F. 
Ka over the KE or a. ~ ranges. 
Simulation algorithms were coded in Pascal and 
TurboPascal and compiled on IBM Personal Computers. Mos t o f 
the equations we used were derived from mono , bi and triex-
ponential traditional relationships between concentration 
and time. Calculations of AUC ratios (AUCtest AUCref ) 
depended on the time available for absorption T ( 20. 25 ). 
where T was the end of the absorption period. Derivat ions 
and calculations for one and two model compartments are 
given in Appendix 2. 
T. the time for 99% of the absorption to occur. can be 
estimated from the first order process using the wagner -
Nelson method (22) where the fraction unabsorbed is obtained 
with : 
T 4.606 / Ka eq . 3 
T ranged from 1 . 6 to 5.8 hours. It has been suggested 
that AUC should be calculated at least through 3.5 half 
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lives f or accuracy ( 24 ) . However. it appeared that AUCt at 
t =2T is usually within a few percent of the AUCinf ( 17 , 24 ) . 
For the two compartment study. the procedure was similar 
except the classic triexponential function ( equation 2 ) 
describing an open two compartment model. If we maintain our 
assumption that v. K21. D, a and ~ remain constant and inde -
pendent of time. we can express the extent of absorption as 
At = f Ctdt eq.4 
Using the ranges of pharmacokinetic parameters reported and 
reference values from table III. area under the curves were_ 
calculated using the trapezoidal rule (AUCt ) and equations 
previously defined (AUCinf) : the area at t = infinity was 
A= F.D / V. KE eq . 5 
for one compartme nt a nd 
A = AT + [ CT / a + CT I ~ 
for two compartme nts 
eq.6 
AUC rat i os ( test / ref) were than evaluated. Time points 
such as t= T, 3 / 2T and 2T. 3T were given special attention. 
This study is not exhaustive in any means because we had to 
use a limited set of parameters. Nevertheless , this report 
presents an approach in the potential use of truncated area 
in bioequivalence determination. 
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RESULTS AND DISCUSSION 
Area under the curve ratios have been discussed by 
Wagner ( 24 ) and Loo and Riegelman (2 5 ) who proposed several 
mathematical relations for percent of drug absorbed. inde -
pendent of the model. Incomplete availability can influence 
the absorption process and true absorption rate constants 
cannot be calculated with complete accuracy from plasma 
levels ( 27 ). Furthermore. when the absorption is the limit -
ing factor. flip-flop phenomena may occur ( Ka <KE ) and 
AUCinfcannot be correctly estimated (28) . In other in--
stances . when both zero and first order kinetic model 
describe the absorption process ( 29 ) . the rate of absorption 
is very difficult to estimate with accuracy. For bioe-
qui valence testing, however. the extent and rate of 
absorption , as measured from blood concentrations , by com-
paring using AUCs , Tmax and Cmax do not fall within the 
previous limitations. In this study, the Ka ' s are apparent 
absorption rate constants and represent also immediate 
release characteristics of the dosage forms being tested . We 
fully understand the limitations of the simulations since 
the pharmacokinetic models apply to situations where the 
formulation behavior is the limiting factor of drug absorp-
tion . 
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I n many bioe qui va lence stud ies. an anal ys i s of var iance 
is conducted on pharmacokinetic par ame ters such as Ct or 
AUCt a nd t he class i cal hy p otheses a re te s ted: 
H0 : Test = Reference or ~ = O 
Ha . Test # Referenc e o r ~ # 0 . where ~ is a measure of 
the difference in bi oa vailability . Th i s t e st i s n ot cons i s -
t ent wi th the definiti on o f bioequivalenc e be c ause the powe r 
o f the test is aimed at testing Ha not the null hypothesi s 
H0 The current acceptance criteria f or bioequivalenc e i s 
that the true AUG or AUCinf of the t est f ormulation s h ould 
be within 20% of the reference mean : 
AUCtest - AUCref ~ 10. 20 1 ( AUCref ) 
which can be written as: 
I 0. 2 I 
Therefore the AUG ratios are c ompatible with the nature 
of bioequivalence testing . 
In a previous investigation ( 16 ) three cases of bioe-
quivalence testing were simulated. In all simulations the 
truncated area under the curve ( AUCt ), accounting for 6 0% o f 
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the AUCinf ' resulted in making the tests more sensitive to 
bioavailability differences. It was also anticipated that 
the ratios of AUCtmax could be of critical importance fo r 
the determination of bioequivalence as it i s intimately re -
lated to the rate of absorption . Unfortunately. we fou nd 
that f or high bioavailability ( F ) . and low rate of absorp-
tion ( Ka ) ( 50 to 75% of the reference value ). the 
AUCtmax still falls within the acceptable range 80- 120% In 
other cases. the AUCtmax ratio did not indicate equivalence 
for bioequivalent products . The AUCtmax ratios are not reli -
able indicators of the absorption rate as they failed to_ 
indicate equivalence in instances when Ka and relative 
bioavailability were actually within the acceptable 20% of 
the reference value ( Table IV ). In the bioavailability 
profiles illustrated in figure 3. drug product B having a Ka 
of 2.0 ( 143% of the reference value ) with a relative 
bioavailability of 70%, and drug product C having a Ka of 
0.8 ( 50% of the reference 
bioavailability of 130%, 
formulation A. 
value ) with a relative 
were compared to the reference 
All truncated AUC ratios identified the inequivalence 
except when approaching tmax for which the AUC ratios indi -
cated false bioequivalence as marked by the bold vertical 
line . Furthermore , the calculation of this parameter is very 
sensitive t o the sampling regimen and we do not recommend 
its use in bioequivalence comparison . 
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( In this proj e ct. mo re than 700 s imulat ions were per-
formed and analyzed. although only significant figures are 
presented in this report. The discussion is divided into 
three scenarios whi ch we found critical in bioequivalence 
t est ing: l ) the re lat i ve bioavailability (F) is outside the 
acceptabl e range of 80 to 120% 2) the relative 
bioavailability is within the allowed int erval with Ka rang -
ing from 50 t o 200% of the reference v alue . and 3 ) at the 
boundaries o f bioequivalence F=80% and F=l20%. In each case 
the effects of unacceptable performances for the rate of ab-
sorption were c arefully monit ored. 
Case 1: when Ka and F of the test product were both out -
side the range o f 80 to 120% of the reference values. 94% of 
the time the truncated AUG detected the bioinequivalence at 
all time points (tables V and VI ) . In particular situations , 
when the bioavailability is above 120% and the absorption 
rate i s below 80%. the effect of the truncated estimate for 
the extent of absorption is counterbalanced by those two 
parameters and the ratio of truncated areas indicated false 
bioequivalence. As KE or a. C increase , more absorption is 
included in the truncated AUG ( 30 ) and larger portions of 
AUCinf are sens itive to absorption rates. In figure 4 , the 
high relative bioavailability ( F ) compensates for the slow 
rate of bioavailability ( Ka =5 7% ) and AUC ratios indicate 
false bioequivalence. This situation shows that a product 
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wit h unacce pt a b l y hi gh ext ent of absorption and u nacce ptably 
low rate of absorpti on c an be f ound bioequi valent using c er -
tain truncated e s timates . 
Cas e 2 : when the relative bioavailabili ty is within a c -
c eptable ranges and the Ka varies from 50 t o 200% of t he 
reference product , 74% o f the AUCt rati os ( RAT .XX) s h owed 
bioequivalence for only 30% of truly bioequivalent c ase 
products. indic ating that truncated areas are more s ens it i ve 
to the extent than the rate of absorpti on as shown i n table 
v. Nevertheless . the sensitivity o f the AUCt ratios to t he 
rate o f abs orption is proportional to the disposit ion-
phases. It is known that changes in elimination affect phar -
macokinetic parameters of one and two compartment model s 
( 31 ) and this study confirmed that as a consequence . suc h 
changes also influence bioequivalence determination . 
Case 3: at the boundaries , when F=80% . the truncated 
AUC20 is only discriminating when absorption rates are low . 
When F=l20% and Ka is more than 20% of the acceptable limit. 
AUc20 is sensitive to the high rate of absorption. In both 
cases , if you increase the disposition rate constants , 
larger portions of the the AUCinf become discriminating and 
show inequivalence. The percentage of the AUCinf indicative 
of true bioinequivalence due to the absorption rate . varies 
with the elimination phases. Figure 5 illustrates two ex-
amples of minimum AUC ratios required to demonstrate true 
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bioinequivalence. for formulations exhibiting l ow absorpcion 
rate. 
Particular cases where the AUC ratios showed bioine -
quivalence for products with extent and rates of absorption 
within the acceptable range were critical. For all cases ex-
cept a slow elimination rate constants of 0.01 - 1 hrs . when 
F=l20% and the absorption rate constants were high buc 
within the acceptable 100 to 120% of the reference values. 
the truncated AUC ' s for 20 to 50% of the AUCinf indicated 
consistently fal se inequivalence ( Table VII). In our study. 
the truncated racio of AUC accounting for 80% of the AUCinf-
did indicate bioequivalence consistently throughout these 
disposition situations. 
Another limitation when relative bioavialability ( F ) 
ranged from F=lOO to 120% in which AUC and Ka ranged from 67 
to 196.4% the truncated area ratios did not indicate bioine-
quivalence at any time (t) or for any proportional section 
of the AUCinf. The same limitations apply to the use of 
AUCinf in the bioequivalence comparison since AUCinf is in -
dependent of the absorption rate. Within this interval , the 
truncated AUC was completely dependent on the extent of 
bioavailability. 
In all cases , when F was 80 to 120% of the reference 
value , 98% of the time AUC80 was also within the same range 
confirming what had been previously reported (21) on the 
similarity of truncated and infinity AUC ratios. Truncated 
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ratios for early p ortions of the AUCin f were smaller than 
the relative bioavailabi lity ( fi gure 6 ) when the absorption 
rate constant was below the reference value 1 .4 hrs- 1 for 
the test products. Conversely. when Ka was greater than the 
reference value, early truncated area ratios were larger 
than the relative bioavailability ( figure 7 ). The cut-off 
point or time where the truncated AUG rati os became equal t o 
the relative extent of absorpt i on was related to the absorp -
tion rate const ants and exhibited a u-shaped curve in figure 
8 , which indicated that these critical times or percentages 
of AUCinf were high for low absorpt ion rate products.-
decreased as Ka increased and increased again when the rate 
of absorption was above 100% of the re f erence value. The 
slope of AUG ratio Vs. time, in early porti ons of the plasma 
profile . was proportional to rate and extent of absorption. 
This parameter could be an additional est imator t o compare 
absorption kinetics in bioequivalence study and further in-
vestigations are needed on this topic. In our study, the 
cut-off point ranged from 35 to 85% for acceptable formula -
tions ( table VIII). For perfectly bioequivalent products , 
this point could theoretically be 0. The time corresponding 
to these percentages depends on the elimination characteris-
tics , (figure 9 ). Furthermore , if the MEG or MIC [Minimum 
Efficient Concentration or Minimum Inhibi tory Concentration ] 
can be estimated accurately , it has been argued that the 
comparison of truncated AUC 's for bioequivalence purposes 
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has also a pharmacodynamic relevance ( 31 ) . s ince the AUCxx 
ratios compare portions of the plasma levels signif i cant for 
the therapeutic window (figure 10 ) . 
CONCLUSIONS 
A first criticism of the emphasis given t o AUCinf in 
bioequivalence t e st ing was the fact t hat bioequivalence i s 
aimed at comparing the absorption characteristics of two 
dosage f orms. It is well known that AUCinf is not dependent 
on the rate of absorption Ka , thus onl y extent of absorption_ 
could be c ompared with accuracy . 
We feel that extrapolation of the AUCtlast to infinity 
could bring unnecessary variations not representative of 
realistic differences or equivalences between a reference 
and a test produc t. On one hand, if the extrapolated area 
is large , the true difference in extent of absorption may 
become proportionally insignificant. On the other hand, the 
extrapolation is calculated from the last p oints , usually in 
the most variable analytical region and this might introduce 
differences between truly bieoquivalent products. In most 
cases the AUCinf ratios and Auc80 ratios for our simulations 
did not vary significantly indicating that 80% of the AUCinf 
was a good indicator of the extent of bioavailability . 
AUCtmax was not consistently representative of AUCinf or 
rate o f absorption . We do not recommend the use of AUCtmax 
189 
alone to compare bioavalailability because extent and rate 
of absorption outside acceptable ranges can in some cases 
balance each other. 
The proportion of the AUCinf required for sensit i vity in 
bioequivalence testing depends on the combination of 
e limination rate constants and the absorption rate constant . 
In all cases. the AUC ratios at early times overestimated 
relative bioavailability for low absorption rates of test 
products , and underestimated for high absorption rate s 
before reaching the true relative bioavailability val ue. 
Important failures of the truncated areas occurred where the. 
relative bioavailability was high and the rate o f abs orpti on 
was l ower than the reference value as well a s cases where 
acceptable l ow F and l ow Ka led t o false inequivalence as a 
result of a counterbalancing effect . As or KE increased 
-1 
over 0 . 0 1 hr. . larger portions of the AUCinf were neces-
sary to assess bioinequivalence . These simulations suggested 
that 80% of the AUCinf was substantially reliable in the 
range of our study for determining the relative extent of 
absorption which had more influence on bioequivalence than 
the rate of absorption. Although truncated AUC ratios have 
to be further investigated ( as indicators of absorption 
rates ), we feel that examining truncated areas provides ad-
ditional and qualitative information that strengthen 
bioequivalence testing. 
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APPENDIX 1: Nomenclature 
D 
v 
Ka 
hr. - 1 
KE 
in hr. -1 
At 
Ct 
AT 
absorption 
CT 
AUCi. 
AUCref 
AUCtest' 
Ka%: 
cent age 
F% : 
Area 
Area 
reference in 
RATXX 
under 
under 
responding to XX% 
i- inf 
Dose 
Volume of di stributi on 
First order absorption constant in 
First order elimination rate constant 
Distribution rate constant 
Elimination rate constant 
Area under the curve at time t 
Blood concentration at time t 
Area under the curve at the end of the 
period 
Plasma concentration at 
Area Under the Curve 
the Curve for the reference product 
the curve for the test product 
Ratio of Ka test to reference in per -
Ratio of bioavailability test to 
percentage 
Ratio of truncated AUC ' s at t cor-
of AUCinf reference 
at time infinity 
i - tmax : at time of the peak 
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i - t at time t 
APPENDIX 2 : Calculations 
For the one compartment model if t ~ T. blood levels are 
given by eq.l and the extent of absorption can be integrated 
and written as ( 21. 22 ) : 
At eq. 
where At is the area under the blood level-time curves • 
from 0 to time t. The following ratios can be derived (21) 
where Ka' and F' indicate the pharmacokinetic parameters for 
the reference product: 
At F 
eq. 2 
If t , T the plasma levels can be described (17) by : 
Ct CT . e -KE(t-T) eq . 3 
where CT is the blood concentration at time T . thus the 
AUC at time t can be written (2 1 ) as : 
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At; AT - Ct. ( l - e-KE( t - T )) .l / KE eq . 4 
with AT. the area unde r the curve from time O to T. The 
rat ios can the r efore be calcul ated ( 2 1 ) : 
At 
AT ' At " + ( 1- e - KE ( t - T•) ) . Ct / KE 
For the two compartment model if t T , 
therefo re . At can be derived 
At 
F . D. ( K21 - Ka ) 
-v~r a =Ka)~\~=Ka)-
a 
1 
- ~ -
eq. 5 
+ 
+ 
eq .6 
The area under the curve at t infinity can be derived 
from equation 9 and calculated using the pharmacokineti c 
parameters independent of time : 
A + 
a 
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1 
-~ - + 
eq .7 
The ratio At / At * can also be estimated easily . On the 
other hand. if t >T , the blood levels can be expressed as: 
Ct ~ CT eq.8 
therefore , At the area under t he curve at time t can be in -
tegrated and written as: 
At AT + (1-e - a ( t - T) ].CT/ a + (1 -e-~(t -T ) ].CT / ~ eq.9 
The area at t - infinity is derived in equation 10 
A AT + [ CT / a + CT I ~ ] eq. 10 
and the ratios can be calculated from At / At • : 
At AT+ (1-e-a (t - T)].CT / a + (1-e - ~(t-T)) .CT I ~ 
eq . 11 
At 0 AT "+ (1-e-a(t - T) ) . CT 0 1a + (1-e-~(t-T)) .CT · / ~ 
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with T 4.606 Ka and T 4 .606 Ka. In this parcicular 
case. AT and AT· are calculated from equacion 9 and CT. CT· 
from 
equati on 2 for c~T. 
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Table I : One compartment model simula tions 
Parameters 
Variable Parameters 
Elimination rate constant KE l/hr 0.04, 0.08, 0.12, 0. 1 6 , 0.2 
0. 8' o. 9 ' 1. 0' 1.1, 1. 2' 1.)' 
Absorption rate constant Ka l/hr 1. 4' 1. 5 , 1. 6 ' 1. 7 ' 1. 8' 1. 9 
Absorption Period T hrs. 5 . 7 4' 5.12 , 4.60, 4' 18' ) . 84' ) . 4 
J. JO' ). 06, 2.88, 2.70, 2.56, 2. 4 
Relative bioavailability 0. 7' 0.8, 0.9, 1. 0, 1.1, 1. 2' 1.) 
Constant Parameters 
Volume of distribution Vd 1 10 
Dose D mg 1000 
Sampling Regimen in hours: 0. )) ' 0.67, 1. 0' 1. 5' 2.0, 2 . 5 ' ) . 0' 4 . 0 
5. o, 6.0, 8. 6' 10, 12, 16, 48, 72, 96 , 1 20 
>-' 
<D 
<D 
Table II : Two Compartment Model Simulations 
Parameters 
Variable Parameters 
Disposition Rate Constants QI l/hr 0. 17, 0.32, .0.4 7, 0.63, 0.79 
p l/hr 0 .01, 0.09, 0. 17 
Absorption Rate Constant Ka l/hr 0.65, 0 . 95, 1. 4. 2. 0. 2.7 5 
Absorption Period T hrs 7.08, 4.84, 2 . 30, 2.30, 1. 68 
Relative Bioavailability F 0.6, 0. 8. 1. o, 1. 2. 1. 4 
Constant Parameters 
Volume distribution V 1 10 
Dose D mg 1000 
Sampling Regimen: 1. 0, 1. 5, 2. 0. 2 . 5. 3. 0. 4. o, 5.0, 6. 0, 7.0, 8.0 
10, 12, 15, 24, 48, 72, 96, 120, 144, 168, 192, 
216 (hours) 
ti) 
0 
0 
Table III : Pharmacok inetic Parameters of the Refere nce Produc ts 
One compartment model 
First Order Absorpt i on Rate Ka : 1. 4 l / hr. 
Bioavailability, F : 1. 0 
Two compartment model 
First Order Absorption Rate Ka : 1. 4 l/hr. 
Disposition K21: 0. 2 l/hr . 
Bioava ilabi 1 i ty F : 1. 0 
ti) 
0 
~ 
Table IV: Pharmacokinetic 
Relevance of AUCtmax 
Ka% F% AUCtmax AUC48 AUC120 
Ratio Ratio ratio 
One Compartment Model 
94.0 0 . 8 0.78 0.80 0.80 
87.5 0.8 0.76 0.80 0.80 
50.0 1. 3 0.94 1. 30 1. 30 
75.0 1. 3 1.16 1. 30 1. 30 
Two Compartment Model 
142.8 0.7 0.81 - 0.69 
50.0 1. 3 0.87 - 1. 30 
78.5 1. 3 1. 15 - 1. 30 
85.7 0.8 0.74 - 0.80 
ro 
0 
ro 
KE 
0.04 
0.20 
Table V : One Compartment model, AUC ratios for bioinequivalence 
F% KA% RAT.20 RAT.30 RAT.40 RAT . 50 RAT. 60 RAT. 80 
70 57 0.63 0.66 0.67 0.68 0.68 0.68 
70 143 0.73 0. 71 0. 71 0.71 0.70 0.70 
130 57 1.17 1. 23 1. 25 1. 29 1. 39 1. 30 
130 143 1. 35 1. 32 1. 32 1. 31 1. 31 1. 30 
70 57 0.50 0.56 0.58 0.61 0.63 0.68 
70 143 0.81 0. 77 0.75 0.74 0.72 0.71 
130 57 0.94 1. 03 1. 07 1.13 1.17 1. 27 
130 143 1. 51 1. 43 1. 40 1. 37 1. 34 1. 31 
RAT.XX AUC ratios (test to reference) at XX% of the AUC infinity 
ti) 
0 
VJ 
F% 
KA% 
RAT20 
RAT30 
RAT40 
RAT50 
RAT60 
RAT70 
RAT80 
Table VI : 
60 
46 
0.585 
0.590 
0.593 
0.596 
0.597 
0.598 
0.599 
Bioinequivalent Rroducts-AUC Ratios 
Twocompartment Model 
140 
196 46 196 
0.600 1. 35 1. 40 
0.600 1. 37 1. 40 
0.600 1. 38 1. 40 
0.600 1. 39 1. 40 
0.598 1. 39 1. 40 
0. 599 1. 40 1. 40 
0 . 600 1. 40 1. 40 
"' 0 
"' 
Table VII : 
Ke 
0 . 04 
0.12 
0. 20 
'0.01 
0 . 03 
0.09 
0.17 
False Inequivalence 
(for F = 120% and Ka = 114%) 
RAT20 RAT40 RAT60 RA TSO MODEL 
1. 22 1. 22 1. 2 1 1. 20 0 
1. 24 1. 24 1. 22 1. 20 N 
1. 27 1. 25 1. 2 4 1. 21 E 
1. 20 1. 20 1. 19 1. 19 T 
1. 27 -- -- 1.19 w 
1. 28 1. 21 1. 19 1. 19 0 
1. 30 1. 27 1. 2 2 1.19 
ti) 
0 
(Jl 
Table VIII: Truncated AUC Ratios equating Relative Bioavailability 
Time and Corresponding \ of AUCinf 
One Compartment 
KE (l/hr) 0.04 0. 12 0.20 
Ka (l/hr) 1. 2 1. 7 1. 2 1. 7 1. 2 1. 7 
F=0.7 
Time (hr.) 16 12 24 24 24 24 
\ AUCinf 46 36 61 61 61 61 
F=l.O 
Time (hr.) 14 14 15 15 15 15 
\ AUCinf 74 74 84 84 84 84 
F=l. 3 
Time (hr.) 13 13 14 13 14 14 
\ AUCinf 84 84 89 84 89 89 
Two Compartment 
' 
(l/hr) 0.01 0.09 0.17 
Ka (l/hr) 0.95 2.00 0. 95 2.00 0.95 2. 00 
F=0.6 
Time (hr.) 24 10 12 7 7 6 
\ AUCi nf 32 13 70 49 82 75 
F=l.O 
Time (hr.) 36 12 15 8 15 9 
\ AUCinf 39 16 78 5 4 87 65 
F=l. 4 
Time (hr.) 48 24 15 9 9 5 
\ AUCinf 52 32 78 59 90 65 
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APPENDIX A 
In early stages of the wet granulation experiment. a 
power meter or wattmeter , was connected between the power 
and our planetary mixer in order to validate the end - point 
determination. A plotter was wired to the meter to record 
the variation in the power needed to rotate the paddle 
within the granulation. Thus if the courant can be assumed 
to be constant. one has a fair approximation of the torque 
or resistance to movement of the mass being granulated. 
The apparatus was improved and the wattmeter was 
connected with a interface and an IBM PC. A data acquisition 
software averaged and reduced the noise thus allowing the 
recording of clear variation wattage. Figure 1 is a typical 
power consumption t race for ibuprofen formulations without 
the computerized interface. 
Figure 2 is a calibration curve used in the dissolu-
tion experiment. Ibuprofen concentration were measured by 
ultra violet spectrophotometry at 264 nm. 
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APPENDIX B 
X- RAY CRYSTALLOGRAPHY AND MOLECULAR MODELING 
223 
Single X- ray diffraction data o f rac - ibuprofen and 
(-)- S- ibuprofen were used with the "macromodel " software t o 
examine the 3D molecular packing in the crystal lattice 
( figures 1 to 5 ) . 
From single crystal coordinates it was a simple mat-
ter to generate powder X- ray diffractograms. Thus it was 
possible to predict and validate the single powder X-ray 
crystallography (figure 6 ) . however. the intensities were 
dependant on how randomly the crystal is oriented in the 
x-ray beam. Therefore. only the position of the peaks could 
be predicted not the optical purity. 
224 
l'lour• 1: llolecul•r P•cklno in th• 
cryat•I l.8ttlc• of Ru-ibuprofen 
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,...,. 2: llepr•-t•tloll et tH l+l-1M1prefe11 
orretal lattioe ,,_ • 41fferut ..... 
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l'lfUt• S: Arroyo of <•l-1 - <-1-11 11...,010• 
llolecllloo Ill Ill• oryotal of rac-lt...,ofoa 
(Doo• -· oro hydr- bolMlol 
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APPENDI X C 
THERMAL ANALYSIS : VALIDATION OF THE EXPERIMENTAL DESIGN 
231 
( 
Differ e ntia l Scanni n g Calorimetry Procedures 
DSC scans of all ingredients of the formulations in -
eluding ibuprofen. were performed ( Figures to ) . 
Qualitative assessment of all melting characteristics were 
evaluated to check if the thermal behavior of excipient s 
will affect the fusion of the pure active drug in the range 
of 70 to 79 °c and 45 to 60 °c. Physical mixtures were also 
tested for endotherms and compared to pure ibuprofen. From 
all the thermograms analyzed. there was no evidence of ad-
verse interference in the range of our study. 
When necessary. the fusion parameters ( Tm and~ H ) 
were recalculated from the indium standard using the foll ow-
ing equations: 
K ~Hf Mc 
----------Ac equation 1 
K . M As 
-----Ms _____ _ equation 2 
with K: the calibration constant; Mc: the mass of 
I ndium; Ac: the area under the thermogram for the calibrant; 
As : the peak area of the sample: M: the MW of the sample 
232 
Purity Determination: 
Using a differential scanning calorimetry method. it 
was p ossible to validate the enantiomeric purity of the (+)-
S-ibuprofen. This thermal approach has been described in the 
Thermal Analysis Newsletter #3. and ¥5 by A.P Gray and 
edited by Perkin-Elmer . Norwalk Conn. The method consisted 
of calculating the amount of impurities from the melting 
point depression 
6T To - Tm equation 3 
and using the Van ' t Hoff equation: 
To-Tm 
with To 
Tm 
R 
X2 
RTo2 equation 4 
Absolute melting temperature of the sample 
the experimental fusion temperature 
the enthalpy of fusion in cal / mole 
- 1 0 - 1 the molar gas constant:l.987cal.mole . K 
the mole frcation of impurity 
The fraction melted can be calcuated from 
F ( To - Tm) / (To-Ts) equation 5 
233 
and Ts ~ To - ( To -Tm). l F equation 6 
with Ts: the melting point of the sample for a given 
fracti on melted. 
F Fraction melted 
Fr om a DSC scan of the pure indium, the angle a was 
determined ( figure 16 ) and used in figure 17 t o obtain true 
values of melting. The cor responding fracti on mel ted were 
calculated. 
Ts was plotted against l / F in figure 18 . The inter -
cept To and the slope were derived from the straight line 
and used in equation 4 to produce the amount of impurities . 
In (+)-8-ibuprofen , X2 the mole fraction of impurit ies 
ranged from 0.0081 to 0.0115. Thus the purity of this com -
pound ranged from 98.85 to 99.18 %. It is not known if the 
impurities responsible for Lattice deffects might be in part 
( - )-R- ibuprofen molecules. Enanti omeric purity was also in -
vestigated with phase diagrams in manuscript V. 
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Piqure 1: Typical DSC thermogram of Ethyl ibuprofen 
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Figure 2: DSC scan of Polyvinyl Pirrolidone (Povidone) in 
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Figure 3: DSC ~=an of Na Starch Glycolate (Explotab) in the 
temperature range of interest 
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riqur• 5: Example of a typical endotherm of Ethyl ElJl; 
An 77\ ibuprofen formulation with l\ of 
disintegrant 1/3 intrgranular 
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Figure 6: Example o f a typ i cal endotherm of a ground 
ibuprofen tablet obtained at regular compaction 
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Fiqure 7: Example of a typical endotherm of a ground 
physical mixture (before wet granulation) 
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Figure 81 Typical Endotherm of (+)-S-ibuprofen 
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Figure 9: Endotherms of (+)-S-ibuprofen and rac-ibuprofen 
recrystallized at 4°c from methanol liquors. 
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~iqure 10: Thermogram of a Sand racemate mixture (25- 75) 
melted and recrystallized at 4 °c 
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Fiqure 111 Example of s and racemate physical mixtures 
[(75-25\)-24 hours-Labshaker-Room Temperature] 
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riqure 12: Thermogram of a directly compressible (+)-S-
ibuprofen formulation [24 hours of mixing] 
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riqure 13: Thermogram of a directly compressible 
(+)-S- ibuprofen formulation [72 hours of mixing] 
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Piqure 15: Thermogram of a ground (+)-S-ibuprofen tablet 
obtained at 1200 lbs 
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Fiqure 16: High Purity I ndium Melt 
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Fiqure 17: DSC Scan of Ibuprofen 
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Figure 18 
(+)-8-lbuprofen Purity Determlnetlon 
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APPENDIX D 
EXPERIMENTAL COMPLEMENT OF MANUSCRIPT II 
253 
( 
In this work other experiments were performed to 
complement the results. However I found some of it incom-
plete or noc statistically powerful. Therefore. in agreement 
with the authors it was deci ded not to incorporate these 
data in the manuscript for publ ication. Some of the data is 
graphically presented in figures 1 and 2 or tabulated (table 
I ) . 
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Table I: Pure ibuprofen Compacted: Thermal Analysis 
Compaction 4H 1 Tm 
Level in KN (J/g) ( 'C) 
Mean (SD) 
0 127.1 77.5 
1(1) 127.8 75.3 
N 8(3) 124.5 74.7 (Jl 
-'1 30(3) 125.0 75.5 
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